Conditions: Autoimmune Hepatitis Autoimmune Chronic Hepatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.

Detailed description:

Arms:
arm 1: Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed. arm 2: Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed. arm 3: Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.

Interventions: intervention 1: RO7049665 intervention 2: Placebo
Intervention descriptions: intervention 1: RO7049665, subcutaneous injection, Q2W. intervention 2: RO7049665-matching placebo, subcutaneous injection, Q2W.

Protocol document:
Prot_SAP_000.pdf: 
 
Official Title: 
A Double-Blind, Randomized, Parallel-Group, Phase 2 Study to 
Investigate the Effect of RO7049665 on the Time to Relapse 
Following Steroid Tapering in Patients With Autoimmune Hepatitis 
NCT Number: 
NCT04790916 
Document Date: 
Protocol Version 2: 05-Aug-2021 
 
 
 


FINAL PROTOCOL APPROVAL
CONFIDENTIAL
The information contained in this document, especially any unpublished data, is the property of 
F. Hoffmann-La Roche Ltd (or under its control) and therefore, is provided to you in confidence as 
an Investigator, potential Investigator, or consultant, for review by you, your staff, and an 
applicable Ethics Committee or Institutional Review Board. It is understood that this information 
will not be disclosed to others without written authorization from Roche except to the extent 
necessary to obtain informed consent from persons to whom the drug may be administered.
RO7049665 —F. Hoffmann-La Roche Ltd
Protocol BP42698, Version 2
PROTOCOL
TITLE:
A DOUBLE-BLIND, RANDOMIZED, 
PARALLEL-GROUP, PHASE 2 STUDY TO 
INVESTIGATE THE EFFECT OF RO7049665 
ON THE TIME TO RELAPSE FOLLOWING 
STEROID TAPERING IN PATIENTS WITH 
AUTOIMMUNE HEPATITIS
PROTOCOL NUMBER:
BP42698
VERSION:
2
EUDRACT NUMBER:
2020-003990-23
IND NUMBER:
NA
TEST PRODUCT:
RO7049665
SPONSOR:
F. Hoffmann-La Roche Ltd
DATE FINAL:
Version 1: 15 September 2020
DATE AMENDED:
See electronic date stamp below
 
Company Signatory
Approver's Name
Title
Date and Time (UTC)
05-Aug-2021 14:33:23


RO7049665 — F. Hoffmann-La Roche Ltd
2/Protocol BP42698, Version 2
PROTOCOL ACCEPTANCE FORM
TITLE:
A DOUBLE-BLIND, RANDOMIZED, 
PARALLEL-GROUP, PHASE 2 STUDY TO 
INVESTIGATE THE EFFECT OF RO7049665 
ON THE TIME TO RELAPSE FOLLOWING 
STEROID TAPERING IN PATIENTS WITH 
AUTOIMMUNE HEPATITIS
PROTOCOL NUMBER:
BP42698
VERSION NUMBER:
2
EUDRACT NUMBER:
2020-003990-23
IND NUMBER:
NA
TEST PRODUCT:
RO7049665
SPONSOR:
F. Hoffmann-La Roche Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator’s Name (print)
Principal Investigator’s Signature
Date
Please keep the signed original form in your study files, and return a copy to your local 
Site Monitor.


RO7049665 — F. Hoffmann-La Roche Ltd
3/Protocol BP42698, Version 2
PROTOCOL AMENDMENT, VERSION 2
RATIONALE
European Association for the Study of the Liver (EASL) provides guidelines for the 
diagnosis and treatment of patients with Autoimmune Hepatitis. However, not all 
countries and sites adhere to the EASL guidelines and have instead developed their own 
local rules and practices. Therefore, protocol BP42698 has been amended to 
incorporate the following changes based on feedback from sites and investigators, in 
order to better adapt the eligibility criteria for the patients to the local practices. Changes 
to the protocol, along with a rationale for each change, are summarized below.

Section 5.1 (inclusion criteria #4, #5 and #7): 
o
Inclusion criterion 4: changes have been done to clarify the IgG measurements 
and local practice and to adapt the time in biochemical remission to local 
practice.
o
Inclusion criterion 5: stable use of corticosteroid (CCS) non-specific 
immunosuppressants has been updated to 3 months instead of 6 months, and 
without dose increase in the 6 months prior to the randomization.
o
Inclusion criterion 7: conditions around previous CCS tapering were adjusted.

Section 8.2.2. (Vital signs): A new body area (forehead) has been introduced for 
body temperature measurements based on a request by a South Korean site.

Section 8.3.7. (Management of specific adverse events): The text regarding the role 
of the Medical Monitor has been updated.
Additional minor changes have been made to improve clarity and consistency. 
Substantial new information appears in Book Antiqua italics. This amendment represents 
cumulative changes to the original protocol.


RO7049665 — F. Hoffmann-La Roche Ltd
4/Protocol BP42698, Version 2
TABLE OF CONTENTS
PROTOCOL ACCEPTANCE FORM .................................................................... 2
1.
PROTOCOL SUMMARY............................................................................. 12
1.1
Synopsis................................................................................ 12
1.2
Schematic of Study Design.................................................... 19
1.3
Schedule of Activities ............................................................ 19
2.
INTRODUCTION ........................................................................................ 24
2.1
Study Rationale ..................................................................... 24
2.2
Background ........................................................................... 24
2.2.1
Autoimmune Hepatitis............................................................ 24
2.2.2
RO7049665 ........................................................................... 25
2.2.2.1
Previous Clinical Studies ....................................................... 26
2.3
Benefit/Risk Assessment....................................................... 29
3.
OBJECTIVES, ENDPOINTS, AND ESTIMANDS ....................................... 32
3.1
Primary estimand................................................................... 33
3.1.1
Treatment .............................................................................. 33
3.1.2
Endpoint ................................................................................ 33
3.1.3
Intercurrent Events ................................................................ 34
3.1.4
Summary Measure ................................................................ 34
3.1.5
Sensitivity Analyses............................................................... 35
4.
STUDY DESIGN......................................................................................... 35
4.1
Overall Design ....................................................................... 35
4.1.1
Length of the Study ............................................................... 36
4.1.2
Stopping-rules Criteria........................................................... 37
4.1.3
Individual Stopping Criteria.................................................... 37
4.1.4
Communication Strategy ....................................................... 38
4.1.5
Administrative Structure......................................................... 38
4.2
Scientific Rationale for Study Design..................................... 38
4.2.1
Rationale for Study Population .............................................. 38
4.2.2
Rationale for Control Arm ...................................................... 39
4.2.3
Rationale for Biomarker Assessments................................... 39
4.3
Justification for Dose ............................................................. 41


RO7049665 — F. Hoffmann-La Roche Ltd
5/Protocol BP42698, Version 2
4.4
End of Study Definition .......................................................... 41
5.
STUDY POPULATION................................................................................ 42
5.1
Inclusion Criteria.................................................................... 42
5.2
Exclusion Criteria................................................................... 44
5.3
Lifestyle Considerations......................................................... 46
5.4
Screen Failures ..................................................................... 46
6.
TREATMENTS............................................................................................ 46
6.1
Treatments Administered....................................................... 47
6.2
Preparation/Handling/Storage/Accountability ........................ 48
6.3
Measures to Minimize Bias: Randomization and 
Blinding.................................................................................. 49
6.3.1
Method of Treatment Assignment.......................................... 49
6.3.2
Blinding.................................................................................. 49
6.4
Treatment Compliance .......................................................... 50
6.5
Concomitant Therapy ............................................................ 50
6.5.1
Permitted Therapy................................................................. 50
6.5.2
Prohibited Therapy ................................................................ 51
6.6
Dose Modification.................................................................. 51
6.7
Treatment after the End of the Study..................................... 51
7.
DISCONTINUATION OF STUDY, STUDY TREATMENT, AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL................................. 52
7.1
Discontinuation of Study Treatment....................................... 52
7.1.1
Temporary Interruption .......................................................... 52
7.2
Participant Discontinuation/Withdrawal from the 
Study ..................................................................................... 53
7.3
Lost to Follow-Up................................................................... 54
8.
STUDY ASSESSMENTS AND PROCEDURES ......................................... 54
8.1
Efficacy Assessments............................................................ 55
8.1.1
Clinical Outcome Assessments ............................................. 55
8.1.1.1
Efficacy Assessments Completed by Participant 
or Clinician at Site Visits ........................................................ 55
8.2
Safety Assessments .............................................................. 57
8.2.1
Physical Examinations........................................................... 57


RO7049665 — F. Hoffmann-La Roche Ltd
6/Protocol BP42698, Version 2
8.2.2
Vital Signs.............................................................................. 58
8.2.3
Electrocardiograms................................................................ 58
8.2.4
Clinical Safety Laboratory Assessments................................ 59
8.2.5
Safety Biomarker Assessments............................................. 60
8.2.6
Local Pain and Skin Reactivity Assessments ........................ 60
8.2.7
Medical History and Demographic Data ................................ 60
8.3
Adverse Events and Serious Adverse Events ....................... 61
8.3.1
Time Period and Frequency for Collecting 
Adverse Event and Serious Adverse Event 
Information............................................................................. 61
8.3.2
Method of Detecting Adverse Events and Serious 
Adverse Events ..................................................................... 61
8.3.3
Follow-Up of Adverse Events and Serious 
Adverse Events ..................................................................... 62
8.3.3.1
Investigator Follow-Up........................................................... 62
8.3.3.2
Sponsor Follow-Up ................................................................ 62
8.3.4
Regulatory Reporting Requirements for Serious 
Adverse Events ..................................................................... 62
8.3.4.1
Emergency Medical Contacts................................................ 63
8.3.5
Pregnancy ............................................................................. 63
8.3.6
Non-Serious Adverse Events of Special Interest................... 63
8.3.7
Management of Specific Adverse Events .............................. 63
8.4
Treatment of Overdose.......................................................... 64
8.5
Pharmacokinetics .................................................................. 65
8.6
Immunogenicity Assessments ............................................... 65
8.7
Pharmacodynamics and Biomarkers Analyses...................... 66
8.7.1
Genetic and Genomic Analyses ............................................ 67
8.7.1.1
Clinical Genotyping................................................................ 67
8.8
Pharmacodynamics and Biomarker Samples........................ 67
8.8.1
Mandatory Samples............................................................... 68
8.8.1.1
Blood Sampling ..................................................................... 68
8.8.1.2
Tissue Sampling.................................................................... 68
8.8.1.3
Serum and Plasma Samples ................................................. 69
8.8.1.4
Optional Samples .................................................................. 69


RO7049665 — F. Hoffmann-La Roche Ltd
7/Protocol BP42698, Version 2
8.9
Samples for Research Biosample Repository ....................... 69
8.9.1
Overview of the Research Biosample Repository.................. 69
8.9.2
Sample Collection.................................................................. 70
8.10
Medical Resource Utilization and Health 
Economics............................................................................. 71
8.11
Timing of Study Assessments ............................................... 71
8.11.1
Screening and Pre-treatment Assessments .......................... 71
8.11.2
Assessments during Treatment............................................. 71
8.11.3
Assessments at Study Completion/Early 
Termination Visit.................................................................... 72
8.11.4
Follow-Up Assessments ........................................................ 72
8.11.5
Assessments at Unscheduled Visits...................................... 72
9.
STATISTICAL CONSIDERATIONS ............................................................ 72
9.1
Statistical Hypotheses ........................................................... 72
9.2
Sample Size Determination ................................................... 72
9.3
Multiplicity.............................................................................. 74
9.4
Analyses sets ........................................................................ 75
9.5
Statistical Analyses................................................................ 75
9.5.1
Demographics and Baseline Characteristics ......................... 75
9.5.2
Efficacy and Pharmacodynamic Analyses............................. 75
9.5.2.1
Primary Estimand .................................................................. 75
9.5.2.2
Secondary Endpoints ............................................................ 76
9.5.2.3
Exploratory Endpoints............................................................ 76
9.5.3
Safety Analyses..................................................................... 77
9.5.4
Pharmacokinetic Analyses..................................................... 78
9.5.5
Immunogenicity Analyses...................................................... 78
9.6
Interim Analyses .................................................................... 79
9.7
Summaries of Conduct of Study............................................ 80
10. REFERENCES ........................................................................................... 81
11. SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS.................................................................................... 83


RO7049665 — F. Hoffmann-La Roche Ltd
8/Protocol BP42698, Version 2
LIST OF TABLES
Table 1
Schedule of Activities – Main Table ........................................... 20
Table 2
Schedule of Activities – Detailed Table....................................... 22
Table 3
Schedule of Activities – Corticosteroid Tapering Schedule......... 23
Table 4
Serum Pharmacokinetic Parameters of RO7049665 after 
Single Subcutaneous Administration .......................................... 28
Table 5
Objectives and Endpoints ........................................................... 32
Table 6
Intercurrent Events and the Statistical Treatment ....................... 34
Table 7
Summary of Treatments Administered........................................ 47
Table 8
Decision Tree for ALT or IgG Increase ....................................... 55
Table 9
Summary of the Group Sequential Design.................................. 73
Table 10
Analysis Sets .............................................................................. 75
Table 11
Safety Statistical Analysis Methods ............................................ 78
LIST OF FIGURES
Figure 1
Overview of Study Design........................................................... 19
LIST OF APPENDICES
Appendix 1
Regulatory, Ethical, and Study Oversight Considerations........... 84
Appendix 2
Adverse Events: Definitions and Procedures for Evaluating, 
Follow-up and Reporting............................................................. 93
Appendix 3
Procedures for Recording Adverse Events ............................... 101
Appendix 4
Clinical Laboratory Tests .......................................................... 106
Appendix 5
Contraceptive Guidance and Collection of Pregnancy 
Information................................................................................ 109
Appendix 6
Patient-Reported Outcome (PRO) Assessments...................... 113


RO7049665 — F. Hoffmann-La Roche Ltd
9/Protocol BP42698, Version 2
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation
Definition
ADA
Anti-drug antibody
AE
Adverse event
AIH
Autoimmune hepatitis
ALT
Alanine aminotransferase
ANA
Anti-nuclear antibodies
aPTT
Activated partial thromboplastin time
AST
Aspartate aminotransferase
AUC
Area under the curve
BMI
Body mass index
BP
Blood pressure
CCS
Corticosteroid
CL
Clearance
CLS
Capillary leakage syndrome
Cmax
Maximum concentration
COA
Clinical outcome assessment
CSR
Clinical study report
CTCAE
Common terminology criteria for adverse events
DNA
Deoxyribonucleic acid
EC
Ethics committee
ECG
Electrocardiogram
eCOA
Electronic clinical outcome assessment
eCRF
Electronic case report form
EASL
European Association for the Study of the Liver
EBV
Epstein-Barr virus
EDC
Electronic data capture
EIH
Entry-into-human
EQ-5D-5L
EuroQoL five dimensions questionnaire-five levels
EU
European union
FACIT
Functional assessment of chronic illness therapy
FDA
Food and drug administration
FFPE
Formalin-fixed paraffin embedded
FSH
Follicle-stimulating hormone
GLP
Good laboratory practice
HBsAg
Hepatitis B surface antigen
HBcAb
Total hepatitis B core antibody
HCV
Hepatitis C


RO7049665 — F. Hoffmann-La Roche Ltd
10/Protocol BP42698, Version 2
HDL
High-density lipoproteins
HIV
Human immunodeficiency virus
HLA
Human leukocyte antigen
IB
Investigator’s brochure
ICF
Informed consent form
ICH
International council on harmonisation
IEC
Independent ethics committee
IHC
Immunohistochemistry
IFN
Interferon
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IL
Interleukin
IMC
Internal monitoring committee
IMP
Investigational medicinal product
IND
Investigational new drug (application)
INR
International normalized ratio
IRB
Institutional review board
IUD
Intrauterine device
IV
Intravenous
IxRS
Interactive (voice/web) response system
LDL
Low-density lipoproteins
LPLV
Last participant, last visit
LPLO
Last participant, last observation
MAD
Multiple-ascending doses
MoA
Mode of action
NK
Natural killer
NOAEL
No-observed-adverse-effect level
NSAESI
Non-serious adverse event of special interest
NSI
Non-specific immunosuppressants
NYHA
New York Heart Association
OLE
Open-label extension
OTC
Over-the-counter
pSTAT5
Phosphorylated signal transducer and activator of 
transcription 5
PD
Pharmacodynamic
PK
Pharmacokinetic
PIIINP
Procollagen III amino-terminal peptide
PRO
Patient-reported outcome (also refers to participant)


RO7049665 — F. Hoffmann-La Roche Ltd
11/Protocol BP42698, Version 2
PROMIS
Patient-reported outcomes measurement information system
PT
Prothrombin time
Q2W
Every 2 weeks 
QoL
Quality of life
QRS
QRS complex
QT
QT interval
QTc
QT corrected for heart rate
QTcF
QT corrected for heart rate using the Fridericia’s correction 
factor
RBC
Red blood cell
RBR
Research biosample repository
RNA
Ribonucleic acid
RR
RR interval
SAD
Single-ascending dose
SAE
Serious adverse event
SC
Subcutaneous
SMA
Smooth muscle antibodies
SoA
Schedule of activities
SoC
Standard of care
tmax
Time of maximum concentration observed
Teff
Effector T cell
Treg
Regulatory T cell
TEAE
Treatment-emergent adverse event
TIMP-1
Tissue inhibitor of matrix metalloproteinase 1
TSH
Thyroid-stimulating hormone
UC
Ulcerative colitis
UDCA
Ursodeoxycholic acid
ULN
Upper limit of normal
US
United States
VAS
Visual analogue scale
Vz/F
Apparent volume of distribution
WBC
White blood cell
WES
Whole exome sequencing
WGS
Whole genome sequencing
WHO
World Health Organization
WOCBP
Women of childbearing potential
WONCBP
Women of non-childbearing potential


RO7049665 — F. Hoffmann-La Roche Ltd
12/Protocol BP42698, Version 2
1.
PROTOCOL SUMMARY
1.1
SYNOPSIS
PROTOCOL TITLE:
A DOUBLE-BLIND, RANDOMIZED, 
PARALLEL-GROUP, PHASE 2 STUDY TO 
INVESTIGATE THE EFFECT OF RO7049665 ON THE 
TIME TO RELAPSE FOLLOWING STEROID TAPERING 
IN PATIENTS WITH AUTOIMMUNE HEPATITIS
SHORT TITLE
Double-Blinded, Parallel-Group, Phase 2 Study for the Effect of 
RO7049665 in Patients with AIH
PROTOCOL NUMBER:
BP42698
VERSION:
2
TEST PRODUCT:
RO7049665
PHASE:
2
RATIONALE
RO7049665 is a novel dimeric interleukin 2 (IL-2) mutein that is being developed as a therapy 
for chronic inflammatory and autoimmune conditions, including ulcerative colitis (UC) and 
autoimmune hepatitis (AIH). It is expected to treat the impaired regulatory T cell (Treg) numbers 
or function associated with autoimmune diseases without the broad-based immunostimulatory
effects of IL-2. Specifically, RO7049665 was engineered to address and overcome the 
pharmacologic, safety, and functional liabilities of aldesleukin, a recombinant human IL-2 
therapy currently approved for the treatment of renal cell carcinoma and malignant melanoma.
Study BP42698 is the first study where RO7049665 is administered to patients with AIH. The 
primary objective of this study is to evaluate the effect of RO7049665 on time to relapse 
following forced corticosteroid (CCS) tapering in participants with CCS-controlled AIH. In 
addition, secondary objectives are to assess the changes in alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and immunoglobulin G (IgG), to investigate the multiple-dose
pharmacokinetics of RO7049665 in this patient population, and to evaluate the safety and 
tolerability of RO7049665 in participants with AIH. The study results will be used to support 
further clinical development of RO7049665.


RO7049665 — F. Hoffmann-La Roche Ltd
13/Protocol BP42698, Version 2
OBJECTIVES AND ENDPOINTS
Objectives
Endpoints
Primary

To evaluate the effect of RO7049665 on 
time to relapse following forced CCS 
tapering as measured by the hazard 
ratio between 7.5 mg RO7049665 and 
placebo.

Time to relapse from start of 
randomization.
Secondary

To assess changes in alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), and IgG over 
time and by dose.

ALT, AST, and IgG (for both , absolute 
and relative [ULN]) over time.

To evaluate the effect of RO7049665 on 
time to relapse following forced CCS 
tapering as measured by the hazard 
ratio between 3.5 mg RO7049665 and 
placebo.

Time to relapse from randomization.

To evaluate the safety and tolerability of 
RO7049665 in participants with AIH.

Incidence and severity of adverse 
events.

Changes in vital signs, physical 
examination, ECG parameters, and 
safety laboratory parameters.

ADA emergence and neutralizing 
potential.
OVERALL DESIGN
Study BP42698 is a 3-parallel arm (two dose levels of RO7049665 versus placebo), 
randomized, placebo-controlled, double-blind, event-driven phase 2 study to assess efficacy of
RO7049665 over placebo in patients with AIH in stable biochemical remission. Two dose levels 
will be assessed: 3.5 mg RO7049665 (subcutaneously [SC], every second week [Q2W]) and 
7.5 mg RO7049665 (SC, Q2W), with matching placebo.
Study Design
This is an event-driven study, which means that participants stay in the study and on treatment 
until the participant experiences an event (e.g., ALT rises > 2 upper limit of normal [ULN] or 
IgG increases > 1.5 ULN), the necessary number of events (a total of 45 events) is reached, 
the participant stops for other reasons or withdraws consent, or the study ends.
Patients eligible for the study must be in biochemical remission for at least 2 years (or less if 
according to the local practice), be on stable treatment (CCSs non-specific 
immunosuppressants [NSIs]) for at least 3 months prior to randomization (and who have not 
had a dose increase 6 months prior to randomization), and show no signs of inflammation (HAI 
≤3) on a liver biopsy taken no more than 12 months prior to randomization. For eligible patients 
this will be the first attempt to taper out CCS completely within the last 3 years.
At study entry, the disease status of the participants should allow for a stepwise removal of all 
immunosuppressive treatment according to local guidelines or practice. If no local guidelines 
exist, EASL guidelines should be applied. Participants will start with study treatment on study 
Day 1 and start tapering CCS use from Day 8 onwards (see tapering schedule, Section 1.3, 
Table 3) to allow for complete CCS withdrawal within a maximum of 12 weeks, depending on 
the starting dose. Last dose of NSI therapy, if any, will be taken on study Day 1.


RO7049665 — F. Hoffmann-La Roche Ltd
14/Protocol BP42698, Version 2
Randomization in a 1:1:1 fashion will occur after patient eligibility is confirmed and before the 
first dose of study treatment is administered. Randomization will be stratified by equivalent 
prednisolone dose (7.5 mg daily versus 7.5 mg daily or dual therapy [CCS any dose, plus 
NSI]). Two interim analyses are planned. The first is planned for futility once 25% of events 
(i.e.,12 events) are observed. The second interim analysis for efficacy and futility is planned 
once 50% of events (i.e., 23 events) are observed.
Treatment Groups and Duration
The investigational medicinal products (IMPs) for this study are RO7049665 or matching 
placebo. The first three doses of study treatment will be administered by the investigational staff 
(i.e., Investigator or study nurse) at the study center under supervision of the Investigator. 
Administration of study treatment should be done in the abdomen. Once the safe administration 
of study treatment is confirmed, it is at the discretion of the Investigator whether to allow 
administration of study treatment at the participant’s home via a home nurse.
Corticosteroids are considered non-investigational medicinal products (NIMPs). 
No dosage modification of RO7049665 is permitted. Participants who have had study treatment 
temporarily interrupted should be considered to restart as soon as medically justified in the 
opinion of the Investigator after discussion with the Sponsor.
Length of Study
The study is anticipated to run for approximately 25 months (i.e., 19 months’ recruitment and 
6 months follow-up), until the necessary number of events is observed. It is not possible to 
estimate the duration of the study for an individual patient as this is an event-driven study; the 
occurrence of an event cannot be reliably estimated for an individual patient. 
Study periods are divided as follows:

Screening: Up to 28 days.

Treatment period: Day 1 to relapse or final number of events is observed.

Safety follow-up: 4 weeks after last administration of study treatment.

End of study visit: Follow-up visit 28 days after last dose of study treatment. In the event 
that a participant is enrolled into an OLE study the follow-up visit will not apply and the 
last visit within the treatment period will be considered as the end of study visit.
End of Study
The goal of the study is achieved when any of the interim analyses results in a decision to stop 
the study or when the required number of events is reached, or if any of the stopping rules 
apply. At this point the study will be unblinded. 
An individual participant has completed the study if he/she has completed all scheduled 
procedures as shown in the Schedule of Activities (SoA; see Section 1.3).
The end of the study is defined as the date when the last participant last observation (LPLO) 
occurs. LPLO is expected to occur approximately 4 weeks after study closure when the final FU 
visit will be conducted. Study closure can occur either after:

The first interim analysis for futility, or

The second interim analysis for futility or efficacy, or

45 events are observed, or

Early study termination.
The Sponsor may set up an open-label extension (OLE) study if RO7049665 development will 
be continued for participants not having had a relapse at the closure of BP42698. 
Internal Monitoring Committee
In order to keep the study personnel blinded during interim analyses, an Internal Monitoring 
Committee (IMC) will be established.
The unblinded IMC will review the results of each interim analysis and will recommend to the 
study team whether the study should stop, continue, or be modified.


RO7049665 — F. Hoffmann-La Roche Ltd
15/Protocol BP42698, Version 2
The IMC is a dedicated group of selected Sponsor representatives, who will be independent 
from the project and review the safety and efficacy data of the study, as well as the interim 
analyses. The roles, responsibilities, membership, scope of activities, time of meetings, and 
communication plan for the IMC will be documented in an appropriate charter.
PARTICIPANT POPULATION
The participants of this study are patients between 18 and 75 years of age, inclusive, with a
diagnosis of AIH, with no evidence of cirrhosis with significant impairment of liver function stage 
(e.g., Child Pugh B or C). All participants in the study will have responded well to treatment with 
CCSs NSIs.
INCLUSION/ EXCLUSION CRITERIA
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Informed Consent
1.
Able and willing to provide written informed consent and to comply with the study 
protocol according to International Conference on Harmonisation (ICH) and local 
regulations.
Age
2.
Between 18 to 75 years of age, inclusive, at the time of signing the informed consent.
Type of Participants and Disease Characteristics
3.
Patients with a definite diagnosis of AIH (type 1, 2 and 3) as per simplified or revised 
original diagnostic criteria (including response to CCSs) (Hennes et al 2008).
4.
Patients who have been in biochemical remission (complete normalization of serum 
transaminases and IgG levels [if IgG is measured, as according to local practice]) for 
2 years (or less if according to the local practice) prior to randomization. At least 
two measurements of IgG levels within normal range at least two weeks apart need to 
be available before randomization.
5.
Patients who have been on stable treatment (CCSs NSIs) for at least 3 months prior 
to randomization and who have not had a dose increase in the previous 6 months prior 
to randomization.
6.
No signs of liver inflammation (HAI 3) on a liver biopsy taken no more than 12 months 
prior to randomization.
7.
Patients with AIH who have previously not attempted (or not attempted in the last 3 
years, if this is the local practice) to taper CCS to 0 mg/day.
Weight
8.
Body mass index within the range of 18-35 kg/m2 (inclusive).
Sex and Contraception/Barrier Requirements
9.
Male and female participants are eligible.
The contraception and abstinence requirements are intended to prevent exposure of an 
embryo to the study treatment. Therefore, the reliability of sexual abstinence for female 
enrollment eligibility needs to be evaluated in relation to the duration of the clinical study 
and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable 
methods of preventing drug exposure.


RO7049665 — F. Hoffmann-La Roche Ltd
16/Protocol BP42698, Version 2
A female participant is only eligible to participate if she is not pregnant, not breastfeeding,
and at least one of the following conditions applies:
Women of non-childbearing potential (WONCBP),
OR
Women of childbearing potential (WOCBP), who:
Agree to remain abstinent (refrain from heterosexual intercourse) or use at least one 
acceptable contraceptive methods during the treatment period and for at least 28 days after 
the final dose of study treatment. 
The following are acceptable contraceptive methods: bilateral tubal occlusion/ ligation, male 
sexual partner who is sterilized, established proper use of hormonal contraceptives that 
inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices, 
male or female condom with or without spermicide; and cap, diaphragm, or sponge with 
spermicide.
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1.
Patients with cirrhosis (F4 fibrosis by Fibroscan®) with significant impairment of liver 
function (Child Pugh category B or C).
2.
Any other autoimmune disease (including overlap syndrome) requiring 
immunomodulating treatment.
3.
History of infection with hepatitis B (hepatitis B surface antigen [HBsAg] positive and/or 
anti-HBc positive; HBV vaccinated patients are eligible), human immunodeficiency virus 
(HIV; positive HIV antibody test), active hepatitis C virus (HCV) infection (detectable 
HCV RNA), detection of replicating CMV or Epstein-Barr virus.
4.
Active infections requiring systemic therapy with antibiotic, antiviral or antifungal 
treatment or febrile illness within 7 days before Day 1.
5.
History of primary or acquired immunodeficiency.
6.
Female patients: Pregnant or lactating.
7.
Symptomatic herpes zoster within 3 months prior to screening.
8.
History of active or latent tuberculosis or a positive QuantiferonGold test.
9.
History of clinically significant severe drug allergies, multiple drug allergies, allergy to 
any constituent of the product, or intolerance to topical steroids.
10. Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or 
squamous epithelial carcinomas of the skin that have been resected with no evidence of 
metastatic disease for 3 years and in situ carcinoma of the cervix that was completely 
removed surgically. Breast cancer within the past 10 years.
11. Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart 
failure New York Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic, 
endocrine, or gastrointestinal disorders (excluding UC).
12. Any condition or disease detected during the medical interview/physical examination 
that would render the patient unsuitable for the study, place the patient at undue risk or 


RO7049665 — F. Hoffmann-La Roche Ltd
17/Protocol BP42698, Version 2
interfere with the ability of the patient to complete the study in the opinion of the 
Investigator.
Prior/Concomitant Therapy
13. CCSs of 5 mg/day (prednisolone-equivalent dose), or < 2.5 mg CCSs 
(prednisolone-equivalent dose) plus immune suppressant, or < 3 mg/day budesonide 
with or without immune suppressant.
14. CCSs 20 mg/day (prednisolone-equivalent dose) or > 9 mg/day budesonide.
15. NSI daily dose higher than recommended standard of care therapy.
16. T or B cell-depleting therapy (e.g., rituximab) within the last 12 months or T- or B-cell 
number below normal due to depleting therapy.
Prior/Concurrent Clinical Study Experience
17. Leukocyte apheresis within 12 weeks of screening.
18. Donation of blood or blood products in excess of 500 mL within 3 months prior to 
screening.
19. Exposure to any investigational treatment within 6 months prior to Day 1.
Laboratory Abnormalities
20.
Abnormal hematologic values:

Anemia (hemoglobin 9 g/dL)

Leukocytosis (white blood cells 2 ULN)

Thrombocytopenia (platelet count 100,000/L)

Thrombocytosis (platelet count 2 ULN)

Eosinophilia (eosinophil count 2 ULN)
21.
Abnormal hepatic enzyme or hepatic function values:

ALT, AST, or alkaline phosphatase, above normal range

Total bilirubin 2 ULN

International normalized ratio (INR) 1.7

Albumin 3 g/dL
22.
Abnormal biochemistry values:

IgG above normal range
Other Exclusions
23.
History of regular alcohol consumption within 2 months of screening defined as:
An average weekly intake of 14 drinks for men or 7 drinks for women. One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces 
(150 mL) of wine, or 1.5 ounces (45 mL) of 80 proof distilled spirits (equivalent 
to 40 vol%).
24.
Any suspicion or history of illicit drug use.
25.
Patients under judicial supervision, guardianship, or curatorship.
NUMBER OF PARTICIPANTS
The study is expected to enroll a maximum of 84 participants (28 participants per arm) in order 
to observe 45 events. Any patient who satisfies all eligibility criteria and who is randomized will 
be evaluable. If the enrolment rate or event rate differ from the assumptions used in these 
calculations, then either the number of participants or the duration of follow-up (or both) may be 
varied in order to ensure the required number of events is observed.


RO7049665 — F. Hoffmann-La Roche Ltd
18/Protocol BP42698, Version 2
CONCOMITANT MEDICATIONS
Any medication used by a participant from 30 days prior to screening until the follow-up visit 
must be recorded in the electronic Case Report Form (eCRF). CCSs and NSIs (e.g., AZA, 
6-MP, MMF, others) used 12 months prior to randomization must be recorded in the eCRF. All 
therapy and/or medication administered to manage AEs should be recorded on the Adverse 
Event eCRF.
The same information must be recorded for the following concomitant medications taken by a 
participant during the indicated period prior to screening until the follow-up visit:
Permitted therapies include:

CCSs and NSIs (e.g., AZA, 6-MP, MMF) used 12 months prior to randomization,

Pre-medication for the management of injection-related reactions (e.g., 
anti-histamines),

Ursodeoxycholic acid (UDCA).
Participants who use the following therapies prior to screening and are on a stable regimen 
should continue their use: 

Oral contraceptives, 

Hormone-replacement therapy,

UDCA,

Maintenance therapy for concomitant diseases.
Participants will taper their CCS therapy for AIH during the first weeks of the study according to 
the SoA table (see Section 1.3, Table 3). As a general rule, no concomitant medication to treat 
the underlying disease other than CCSs during tapering will be permitted. 
Use of the following therapies will be prohibited during the study:

CCS after tapering has been completed, except topical steroids. 

Any other immune system targeted biological therapy (including but not limited to JAK 
inhibitors).
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.


RO7049665 — F. Hoffmann-La Roche Ltd
19/Protocol BP42698, Version 2
1.2
SCHEMATIC OF STUDY DESIGN
An overview of the study design is provided in Figure 1.
Figure 1
Overview of Study Design
1.3
SCHEDULE OF ACTIVITIES
The schedule of the activities (SoA) is provided in Table 1.


RO7049665 — F. Hoffmann-La Roche Ltd
20/Protocol BP42698, Version 2
Table 1
Schedule of Activities – Main Table 
Version 2022-07-29                                                          Week
Screening
1
2
3
4
5
7
9
11
12
13
15
17
19
21
23
25
27
29 / 33 / 37 / 
41 …
31 / 35 / 39 / 
43 …
Unscheduled 
Visit 
Early 
Termination or 
End of Study
Confirmation of 
Relapse
Follow Up 
Visit
Day
D-28  to D-1
1
8
15
22
29
43
57
71
78
85
99
113
127
141
155
169
183
197 / 225  … 
till relapse
211 / 239 … 
till relapse
any time
assessments as 
needed
at least 1 week 
after ALT≥ 2ULN
4 weeks 
after last 
dose
Visit Window
no time
±0 days
±0 days
±1 days
±1 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±2 days
±3 days
Informed Consent
x
Demography
x
Medical History  including AIH and other AIDs
x
Tuberculosis Screening Test
x
Drugs of Abuse + Alcohol Test
x
x
Viral testing  HBV, HCV, HIV, EBV, CMV
x
x
Hormones
x
Previous and Concomitant Treatments
x
Revised AIH Score at diagnosis
x
Simplified AIH Score at diagnosis
x
Out-patient visit in clinic
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Home Nurse Visit (optional, else out-patient visit)
x
x
x
x
x
x
x 
Treatment assignment
x
Administration of Study Medication
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
FU phone call 8-24 hrs past injection
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Anthropometric Measurements (incl. Weight, 
Height [height at screening only] and BMI)
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Vital Signs
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Full physical examination
x
x
x
x
x
x
x
Abbreviated physical examination
x
x
x
x
x
x
x
x
x
ECG-12 lead
x
x
x
x
x
x
x
Hematology
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Coagulation
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Blood Chemistry
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Urinalysis
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Pregnancy Test (WOCBP only, pre-dose)
x
x
x
x
x
x
x
x
x
x
Fibroscan (A)
x
x
x
x
x
x
x
Liver fibrosis testing (A)
x
x
x
x
x
x
x
Liver Biopsy 
x 
x - optional
x
Clinical Genotyping
PK Sample
2
x
x
x
2 (B)  
x
x
x
x
2 (B)  
x
x
x
x
Blood Flow Cytometry 
x
x
x
x
x
x
x (A)  
x
x (C)  
x
Soluble PD biomarkers 
x
x
x
x
x
x
x (D)
x
x
x
Soluble Disease Biomarkers 
x 
x
x
x
x
x
x (D)
x
x
x
Anti-Drug Antibodies
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
PRO - PROMIS SF Fatigue 13a
x
x
x (E)  
x
x
x (D)
x
x
x
PRO - SF-12
x
x (E)  
x
x
x (D)
x
x
x
PRO - EQ-5D-5L
x
x (E)  
x
x
x (D)
x
x
x
ISR Questionnaire
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Research Biosample Repository (RBR) Consent
Adverse Events or Intercurrent Illness
Injection-Related Reaction (IRR) samples (F)  
x
Skin Reactivity, Pain and Size Assessment (G)  
any time
any time
preferred at day 1 but can be collected any time during the study
any time
any time as needed
optional - preferred at day 1 but can be collected any time during the study


RO7049665 — F. Hoffmann-La Roche Ltd
21/Protocol BP42698, Version 2
Table 1
Schedule of Activities – Main Table (cont.)
A.
Every 24 weeks starting from week 25, e.g., week 49, week 74, etc.
B.
The second PK sample can be taken by a mobile nurse, as needed.
C.
If not taken within the previous 4 weeks. 
D.
Every 12 weeks starting from week 25, e.g. week 37, week 49, etc.
E.
At the next scheduled visit approximately one week after the last steroid dose, see also Table 3 (tapering scheme).
F.
Injection-related reaction (IRR) blood samples will be taken at baseline (Day 1 at pre-dose), and at any time in case of IRR of Grade 2 or 
above, for the assessment of tryptase, cytokine panel (exploratory safety biomarkers), and total IgE. PK and ADA will also be collected. 
Baseline samples may only be analyzed in case of IRRs. 
G. In case of an adverse event associated with local tolerability and pain.


RO7049665 — F. Hoffmann-La Roche Ltd
22/Protocol BP42698, Version 2
Table 2
Schedule of Activities – Detailed Table
For footnotes, see Table 1.
Day 
Version 
2021-07-29
Schedule 
Time (h)
PK Sample
Blood Flow Cytometry 
(whole blood)
Soluble PD biomarkers - 
EDTA plasma
Soluble Disease 
Biomarkers - Serum
Anti-Drug 
Antibodies
Liver fibrosis 
testing (A)
Fibroscan
(A)
ISR 
Questionnaire
every two wks
PRO - PROMIS 
SF Fatigue 13a PRO - SF12
PRO - EQ-
5D
Screening
x
x
Day 1
predose
x
x
x
x
x
x
x
x
x
x
Day 1
sampling 
window  
8 - 24 hrs
x
Day 8
predose
x
x
x
x
x
Day 15
predose
x
x
x
x
x
x
Day 29
predose
x
x
Day 43
predose
x
x (E)
x (E)
x (E)
Day 57
predose
x
x
x
Day 71
predose
x
x
x
x
x
x
Day 71
sampling 
window  
8 - 24 hrs (B)
x
Day 78
predose
x
x
x
x
x
Day 85
predose
x
x
x
x
x
x
Day 99
predose
x
Day 113
predose
x
x
x
Day 127
predose
x
Day 141
predose
x
x
x
Day 155
predose
x
Day 169
predose
x
x
x
x
x
x
x
x
x
x
x
Day 169
sampling 
window  
8 - 24 hrs (B)
x
Day 183
predose
x
Day 197, 225 
predose
x
x (A)
x (D)
x (D)
x
x
x (D)
x (D)
x (D)
Day 211, 239 
predose
x
Unscheduled 
Visit 
predose
x
x
x
x
x
x
x
x
x
x
x
Early 
Termination
x
x (C)
x
x
x
x
x
x
x
x
x
Confirmation of 
Relapse
predose
x
x
x
x
x
x
x
x
x
x
Follow Up Visit
x
x
x
x


RO7049665 — F. Hoffmann-La Roche Ltd
23/Protocol BP42698, Version 2
Table 3
Schedule of Activities – Corticosteroid Tapering Schedule
PRO – timepoint where PROs are required in relation to CCS treatment end (see SoA Table 1).
Maintenance  
dose (MD) 
mg/d
Week 
1
Week 
2
Week 
3
Week 
4
Week 
5
Week 
6
Week 
7
Week 
8
Week 
9
Week 
10
Week 
11
Week 
12
Prednisolone
≤20 >15
MD
15
10
10
7.5
7.5
5
5
2.5
2.5
0
PRO
≤15 >10
MD
10
10
7.5
7.5
5
5
2.5
2.5
0
PRO
0
≤10 > 7.5
MD
7.5
7.5
5
5
2.5
2.5
0
PRO
0
0
0
≤7.5 >5
MD
5
5
2.5
2.5
0
PRO
0
0
0
0
0
≤5 >2.5
MD
2.5
2.5
0
PRO
0
0
0
0
0
0
0
2.5
MD
0
PRO
0
0
0
0
0
0
0
0
0
Budesonide
≤9 >6
MD
6
6
6
6
3
3
3
3
0
PRO
0
≤6 >3
MD
3
3
3
3
0
PRO
0
0
0
0
0
3
MD
0
PRO
0
0
0
0
0
0
0
0
0
Version 2020-09-03


RO7049665 — F. Hoffmann-La Roche Ltd
24/Protocol BP42698, Version 2
2.
INTRODUCTION
2.1
STUDY RATIONALE
RO7049665 is a novel dimeric interleukin 2 (IL-2) mutein that is being developed as a 
therapy for chronic inflammatory and autoimmune conditions, including ulcerative colitis 
(UC) and autoimmune hepatitis (AIH). It is expected to treat the impaired regulatory 
T cell (Treg) numbers or function associated with autoimmune diseases without the 
broad-based immunostimulatory effects of IL-2. Specifically, RO7049665 was 
engineered to address and overcome the pharmacologic, safety, and functional liabilities 
of aldesleukin, a recombinant human IL-2 therapy currently approved for the treatment of 
renal cell carcinoma and malignant melanoma.
Study BP42698 has taken into consideration the experience gained in the healthy 
volunteer, entry-into-human (EIH), single-ascending dose (SAD) study WP39826 and 
the ongoing multiple-ascending dose (MAD) study WP40161 in participants with UC. 
Study BP42698 is the first study where RO7049665 is administered to patients with AIH. 
The primary objective of this study is to evaluate the effect of RO7049665 on time to 
relapse following forced corticosteroid (CCS) tapering in participants with CCS-controlled 
AIH. In addition, secondary objectives are to assess the changes in alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and immunoglobulin (Ig) G 
(IgG); to investigate the multiple-dose pharmacokinetics (PK) of RO7049665 in this 
patient population, and to evaluate the safety and tolerability of RO7049665 in 
participants with AIH. The study results will be used to support further clinical 
development of RO7049665.
The rationale for the study design is provided in Section 4.
2.2
BACKGROUND
2.2.1
Autoimmune Hepatitis
AIH was first described by Waldenström in 1950 as “hepatitis sui generis,” characterized 
by a long-lasting amenorrhea with polyclonal elevation of IgG, hyperproteinemia, and 
low serum albumin in young women. Later the autoimmune mechanisms in the 
pathogenesis of this chronic inflammatory liver disease was identified (Gajdusek and 
Mackay, 1958).
AIH is a prototypical autoimmune disease characterized by a loss of immune tolerance, 
robust genetic associations with human leukocyte antigen (HLA) alleles, female 
predominance, elevated aminotransferase levels, and presence of serum 
auto-antibodies (Lammert C. et al 2019). In AIH, autoreactive CD4+ and CD8+ T cells 
break self-tolerance to hepatic autoantigens, potentially as a result of environmental 
triggers and the inability of Tregs to prevent auto-reactivity of conventional T cells. 
Concurrently, in the absence of effective B-cell regulation, autoreactive B cells produce 
auto-antibodies. 


RO7049665 — F. Hoffmann-La Roche Ltd
25/Protocol BP42698, Version 2
AIH may present as acute or chronic hepatitis or as well established cirrhosis; in rare 
cases, it presents as fulminant hepatic failure. Patients experience unspecific symptoms 
like fatigue, upper abdominal discomfort, mild pruritus, anorexia, myalgia, arthralgia, 
rashes (including acne), and amenorrhea. Untreated AIH can lead to liver cirrhosis, 
development of hepatocellular carcinoma, and finally to death (Czaja AJ 2009, Wolf DC, 
2019; Heneghan et al., 2013).
AIH is a rare disease with a prevalence of 16 to 18 affected people per
100 000 inhabitants in Europe (EASL 2015). It can affect people of all ages and sexes, 
though the female to male ratio is approximately four to one (Lowe and John, 2018). AIH 
is characterized by a large heterogeneity of clinical, laboratory, and histological 
manifestations and therefore difficult to diagnose. If hypergammaglobulinemia is present,
AIH should always be taken into consideration (EASL 2015). A simplified AIH score 
(Galaski et al. 2020) has been developed to facilitate the diagnosis in patients with 
histological evidence of hepatitis.
There is currently no approved treatment for AIH. Patients with AIH usually respond 
rapidly to immunosuppressive treatment (CCS +/- non-specific immunosuppressants
[NSIs]) but relapse quickly after its tapering. Most patients need to be on 
immunosuppressive treatment for extended periods and often for life. Side effects of 
long-term immunosuppressive treatment can be quite severe and include osteoporosis, 
muscle wasting, skin manifestations, and endocrine effects like steroid-induced diabetes. 
Therefore, there is an unmet medical need in patients with AIH to replace the current 
standard of care (SoC) with a less burdening maintenance (Mack et al. 2019; Dyson et 
al. 2018; Sebode et al. 2020).
2.2.2
RO7049665
RO7049665 is a novel IL-2 mutein immunocytokine. Compared to aldesleukin, 
RO7049665 has reduced binding affinity to IL-2 receptor (IL-2R)present on CD4and 
CD8effector T cells (Teff) and natural killer (NK) cells, with no loss of binding affinity to 
IL-2R, a required component of IL-2Rreceptors present at the highest levels on 
Tregs. By virtue of its reduced affinity to IL-2Rreceptors and its Treg selectivity, 
RO7049665 enhances the Treg-supporting function of human IL-2 without the 
broad-based IL-2R-mediated immunostimulatory effects of IL-2. RO7049665 therefore 
provides a novel selective immunotherapy to treat autoimmune diseases with an 
expected improved safety profile compared with that of aldesleukin.
In a human whole blood assay, RO7049665 exhibited greatly reduced potency to induce 
pro-inflammatory cytokines compared with that of aldesleukin, with 600-fold lower 
potency for induction of Interferon (IFN), Interleukin 6 (IL-6), tumor necrosis factor 
(TNF), interleukin 1 (IL-1)and 5-fold lower potency for induction of interleukin 8
(IL-8). A tissue cross-reactivity study of RO7049665 showed staining patterns consistent 
with known IL-2R expression profiles. 


RO7049665 — F. Hoffmann-La Roche Ltd
26/Protocol BP42698, Version 2
Observed toxicities in both 4-week and 13-week good laboratory practice (GLP) 
toxicology studies in cynomolgus monkeys treated with RO7049665 were consistent with 
increased pharmacological activity of IL-2 and included skin findings (at the injection site 
and generally), increased heart rate, changes in blood leukocyte numbers (including 
increased eosinophils as well as microscopic findings of tissue infiltrates), and changes 
in lymphoid tissues. Findings were dose-dependent and had resolved or were trending 
to resolution following a 4-week recovery period. At all dose levels tested in both studies, 
there was no evidence for capillary leak syndrome (CLS), a known toxicity of high dose 
IL-2 therapy.
Following subcutaneous (SC) administration of RO7049665 in the 13-week GLP 
toxicology study, exposure to RO7049665 on Day 1 increased less than dose 
proportionally over the dose range of 0.2 mg/kg to 3 mg/kg. Rapid development of 
anti-drug antibody (ADA) was observed at a low dose (0.2 mg/kg), leading to almost 
complete loss of exposure and loss of pharmacodynamic (PD) response by study 
Day 50 in the majority of animals. The no-observed-adverse-effect level (NOAEL) dose
in female animals (that retained exposure to the drug until Day 22) was 0.2 mg/kg 
weekly, with maximum serum concentration observed (Cmax) and area under the curve 
(AUC)0-168h measured on Day 22 as 254 ng/mL and 8440 ng•h/mL, respectively. At 
higher doses (1 mg/kg), a subset of the animals (approximately 50%) did not develop 
high ADAs and remained exposed until the end of the study but developed generalized 
rash. Assessment of PD markers and immune-lineage cell counts in the 13 week GLP 
study confirmed the induction of phosphorylated signal transducer and activator of 
transcription 5 (pSTAT5) and other markers of activation of Tregs, as well as expected 
changes of lymphocyte populations, including transient reduction followed by an 
increase of lymphocyte populations (total T cells, Tregs, CD4T cells, CD8T cells, NK 
cells, and B cells) and monocytes, with the increases of Tregs being of greater magnitude 
than that of other T-cell populations.
2.2.2.1
Previous Clinical Studies
Study WP39826, the first clinical trial where RO7049665 was administered to humans, is 
completed. The aim of this EIH study was to investigate the safety, tolerability, PK, and 
PD of SADs of RO7049665 in a healthy male population. A total of 56 participants were 
administered single doses of RO7049665 or matching placebo injected SC in the 
abdomen. Additionally RO7049665 is currently being evaluated in the ongoing study 
WP40161 with patients with UC. To date 36 patients (male and female) have been 
administered RO7049665 or placebo.
In Study WP39826, a total of nine doses were tested, ranging from 1.5 µg (which was 
the dose based on the minimum anticipated biological effect level), up to 7500 µg. Thirty-
eight participants (67.9%) received one SC injection of RO7049665, and 18 (32.1%) 
received placebo.


RO7049665 — F. Hoffmann-La Roche Ltd
27/Protocol BP42698, Version 2
Overall, RO7049665 was well tolerated. A total of 121 treatment-emergent adverse 
events (TEAEs) were reported across the dose range tested: 94 (77.7%) in the active 
treatment groups, and 27 (22.3%) in the placebo group. Across all groups, the most
frequently reported TEAEs were nasopharyngitis, injection-site erythema, injection-site 
pruritus, headache, diarrhea, and myalgia. The majority of TEAEs were mild in intensity, 
with the exception of 5 events (1 event of gastroenteritis, 3 events of food poisoning, and 
1 event of influenza-like illness) in 5 participants on active treatment, rated as moderate 
in intensity but not related to the study treatment by the Investigator of the study. There 
were no deaths or serious adverse events (SAE), and no withdrawals due to an adverse 
event (AE). There was no trend or pattern in the AEs observed with increasing doses or 
between active and placebo groups, with the exception of local injection-site reactions 
(ISRs; erythema, pruritus), observed in an increasing number of participants proportional 
to the dose increased. All AEs related to the injection site were mild in intensity and 
resolved without treatment.
There were no trends observed in vital signs, electrocardiogram (ECG) intervals, or
laboratory safety results across the dose range tested.
Immunogenicity was assessed, and positive results for ADAs were observed in a total of 
12 participants starting from Cohort 5 (dose of 190 µg). ADAs were of early onset 
(detected in first samples on Day 8 postdose), generally transient, and exhibited dose 
dependency with regard to higher titers and higher incidence. The presence of ADAs
had no apparent impact on the safety, PK, or PD profiles. ADAs did not reveal 
neutralizing potential against endogenous IL-2 as assessed in an assay using 
recombinant human wild type IL-2, which reflects the endogenous counterpart. These 
analyses concluded that the ADAs were not capable of neutralizing endogenous human 
IL-2. 
Serum RO7049665 concentration reached peak level (Cmax) approximately 12 hours 
postdose and declined in an apparent biphasic manner, with a mean apparent terminal 
phase half-life of approximately 72 to 137 hours (see Table 4). Serum exposure levels of 
RO7049665 were below or close to the detection limit in the 1.5 g and 5 g dose 
groups and thereafter increased with increasing doses in a highly variable manner. 
Overall, no obvious deviation from dose-linearity was noted. Sufficient concentration 
data for reliable estimates of non-compartmental parameters in terms of both AUC and 
Cmax was available as of Cohort 6 (650 g) and above (see Table 4). Although the data 
showed moderate between-participant variability, no relevant departure from linearity 
was noted. The mean serum apparent systemic clearance of RO7049665 appeared 
dose-independent and ranged from 1.4 L/h to 2.2 L/h. 
RO7049665 disposition occurred with a mean T1/2 of about 5 days; thus, is expected to 
approach near-complete washout (Ctrough 10% of Cmax) no later than 2 weeks after the 
last dose. Accordingly, no substantial accumulation in reaching steady state is expected 
in a biweekly regimen.


RO7049665 — F. Hoffmann-La Roche Ltd
28/Protocol BP42698, Version 2
At the highest dose of 7500 g RO7049665, exposure was 33% and 65% of the 
exposure at the NOAEL (established in female monkeys on Day 22) in terms of Cmax and 
AUC0-168h, respectively.
Table 4
Serum Pharmacokinetic Parameters of RO7049665 after Single 
Subcutaneous Administration
Dose 
(g)
n
Cmax
(ng/mL)
Tmaxa
(h)
AUCinf
(ng h/m)
CL/F
(L/h)
VZ/F
(L)
T1/2
(h)
Expressed as Geometric means (%CV)
650
6
4.55 
(49.4)
12.00 
(6.00-24.00)
409 
(43.1)
1.59 
(43.1)
210 
(28.2)
91.8 
(52)
2200
6
11.0 
(58.8)
12.03 
(5.98-48.00)
1020 
(37.7)
2.16 
(37.7)
276 
(17)
121 
(23.2)
5000
5
46.5 
(27.4)
12.00 
(12.00-24.00)
2831 
(26.9)
1.77 
(26.9)
331 
(25.6)
130 
(18)
7500
6
68.7 
(85.6)
12.00 
(5.98-12.00
5266 
(55.4)
1.42 
(55.4)
281 
(62.4)
137 
(9.3)
AUCinf area under the serum concentration-time curve extrapolated to infinity; Cmax maximum 
serum concentration observed; CL/F apparent clearance; ND not determined; 
T1/2 terminal elimination half-life; Tmax time to maximum concentration; Vz/F apparent 
volume of distribution. 
a Median (MinMax). 
PD data showed that RO7049665 expanded the Treg-cell pool, thereby delivering proof of 
pharmacology in a healthy population. The Treg expansion was dose-dependent, and 
reached an absolute increase of approximately 200 cells/µL at the maximum tested dose 
of 7500 µg, ranging from 123 cells/µL to 297 cells/µL. This represented a mean fold 
increase of 5.9 (2.9-7.6) from baseline. The peak was, on average, reached on Day 8, 
following a drop at 24 hours postdose, and Treg levels were back to baseline values at 
Follow-up (Day 57). Overall, the estimated therapeutic range of Treg was achieved with 
the doses of 2200 µg, 5000 µg, and 7500 µg, eliciting a mean increase of 2-fold, 4-fold,
and 6-fold, respectively, as compared with baseline. 
There was no expansion of NK cells in any dose group, and no significant trends 
observed in eosinophils. There was no obvious effect on Teff at doses up to 2200 µg. A 
possible weak trend for increase in Teff count occurred with doses of 5000 g and 
7500 g, with mean change from baseline on Day 12 reaching up to 1.5-fold increase 
from baseline.
In the ongoing study WP40161, to date, multiple doses of 3.5 mg and 7.5 mg (to date, 3 
cohorts) were safe and well tolerated, and induced dose-dependent Treg expansions up 
to 5-fold (mean at the highest dose of 7.5 mg) those of baseline. 
The most frequently reported AEs were injection site reactions (ISR) and eosinophilia. 
The majority of AEs reported were mild or moderate (Grade 1 or 2) in intensity except for 


RO7049665 — F. Hoffmann-La Roche Ltd
29/Protocol BP42698, Version 2
a low number of events of severe (Grade 3) intensity, including anemia, eosinophilia and 
hyperkalemia. No events of CLS were reported. Hypersensitivity and injection related 
reactions (IRR) have been reported. All events resolved without sequelae or are 
ongoing. There were no deaths reported to date.
Immunogenicity was assessed, and positive results for ADA were observed in 
approximately 50% of patients of the study. There were no results to date indicating 
ADAs with neutralizing potential against endogenous IL-2.
No significant abnormalities on vital signs or ECG intervals were reported to date and 
besides the changes on eosinophils, no significant laboratory safety results have been 
noted in patients with ulcerative colitis receiving 3.5 mg and 7.5 mg of RO7049665.
Detailed descriptions of the chemistry, pharmacology, PK, efficacy, and safety of 
RO7049665 are provided in the Investigator’s Brochure RO7049665.
2.3
BENEFIT/RISK ASSESSMENT
As mentioned in Section 2.2.1, AIH is a chronic autoimmune disease of unknown cause, 
characterized by continuing hepatocellular inflammation and necrosis; it has a tendency 
to progress to cirrhosis. Some patients go on to develop signs and symptoms of chronic 
liver disease, while others rapidly progress to acute liver failure, as marked by 
coagulopathy and jaundice (Wolf DC, 2019). There is no registered treatment for AIH. 
SoC is CCS, possibly with the addition of NSIs such as, but not limited to, azathioprine
(AZA), 6-mercaptopurine (6-MP) mycophenolate-mofetil (MMF) methotrexate, 
cyclosporine, or tacrolimus. While the vast majority of patients are responsive to CCSs, 
80% of patients relapse when the CCS and /or immunosuppressive treatment is 
withdrawn (van Gerven NM et al. 2013). Untreated AIH has a high mortality rate due to 
the development of liver cirrhosis. Thus, most patients with AIH require lifelong CCS
and/or immunosuppressant treatment and suffer from the side effects of chronic 
treatment, including osteoporosis (particularly worrisome, as AIH is common in young 
women), skin effects, depression, diabetes and metabolic syndrome, infection risk, etc.
The hallmark laboratory findings in AIH are elevated liver enzymes (notably ALT) and 
elevated serum Ig levels, primarily IgG. ALT and IgG are also the recognized disease 
activity markers, and the treatment goal is normalization of these two markers (known as 
“biochemical remission”). In most patients, this can be achieved quickly by induction of 
high-dose CCS therapy followed by the addition of NSIs. After response to induction 
therapy, CCS dose is reduced in a stepwise fashion. Complete withdrawal of 
immunosuppressive therapy is tried after approximately 2 years of stable remission 
(EASL, 2015). However, it is rarely successful; > 80% of patients require re-instigation of 
CCS treatment (van Gerven NM et al. 2013). Patients who relapse twice usually need to 
stay on immunosuppressive treatment for the rest of their life (EASL, 2015). 
RO7049665 represents a potential novel therapy for AIH aiming at long-term, CCS-free 
remission.


RO7049665 — F. Hoffmann-La Roche Ltd
30/Protocol BP42698, Version 2
Study BP42698 is the first study involving dosing of RO7049665 in participants with AIH.
At the time of the commencement of Study BP42698, the safety data in healthy 
volunteers from the EIH Study WP39826 are available, as are some preliminary data 
from the MAD study WP40161 in participants with UC (see Section 2.2.2.1). Potential 
risks have been defined on the basis of clinical experience in healthy volunteers and 
preliminary data from patients with UC, non-clinical pharmacology and toxicology data in 
the relevant animal species, and theoretical risks based on expected PD effects and the 
safety profile of aldesleukin. The doses planned for Arm 1 (3.5 mg) and Arm 2 (7.5 mg) 
are being assessed in study WP40161.
The eligibility criteria, design, and procedures adopted are considered appropriate for 
the safe conduct of the study. Participants will be closely monitored for safety.
Identified potential risks and plans for their mitigation are as follows:

Excessive interleukin-2 effects

Hypersensitivity

ADA formation

Increased Tregs causing immunosuppression

ISRs

Heart rate and 12-lead ECG parameters
For further details, see the RO7049665 Investigator Brochure.
Safety monitoring and risk mitigation measures listed below will be implemented:

Participants will be monitored closely throughout the study for their well-being by a 
phone call following the administration of each dose.

Assessments of ADA development, their neutralizing capability and the impact on 
continued dosing are scheduled throughout the study.
o
Study level stopping criteria relating to hypersensitivity reactions and 
development of neutralizing antibodies to endogenous human IL-2 (see 
Section 4.1.3).
o
Signs and symptoms of autoimmune diseases will be monitored and treated 
according to standard of care.

Procedure-related Risks
The procedures performed include an optional liver biopsy at 6 months to assess 
the inflammation and gain insight on immune cells in the liver tissue, SC injections,
and blood draws. The risks associated with liver biopsies include bleeding, pain, and 
injury to adjacent organs and infection. SC injections may produce a local 
inflammatory reaction, which can range from a slight irritation to infection or possible 
necrosis. The risks associated with blood draws include hematoma, and rarely injury 
to neurovascular structures.


RO7049665 — F. Hoffmann-La Roche Ltd
31/Protocol BP42698, Version 2

Risks Related to Concomitant Medications
Risks of CCS and RO7049665 Adjunctive Therapy
Long-term use of CCSs is associated with pleiotropic effects, which are well 
described (Ford et al. 2011). An increased susceptibility to infection is a known side 
effect. Addition of RO7049665 could theoretically further increase the risk of 
infection. Current SoC includes the addition of other immune-modulating 
therapeutics on a background of CCS therapy, with the goal of therapy being to 
discontinue CCSs, such as in this study. Participants in this study will stop other 
immunosuppressive treatment (if any) before entry into the study (Day –1) and taper 
their steroid dose during the first weeks (see the tapering schedule Section 1.3,
Table 3) while starting with RO7049665. 
To avoid risks associated with immediate withdrawal of CCS, they will be tapered 
slowly (see the tapering schedule Section 1.3, Table 3).

Risk related to being randomized to placebo
Participants eligible for this trial are patients with AIH in stable remission who are 
ready for withdrawal of immunosuppressive treatment in the judgment of the 
Investigator. The chance of being randomized to placebo in this study is 1 in 3. 
Patients in the placebo arm would be treated very similarly to the EASL-
recommended patient management—i.e., stepwise withdrawal of 
immunosuppressive treatment. Being monitored more frequently during the study 
offers the participants the benefit of early detection of a possible relapse justifying 
withdrawal also of combination therapy of CCS plus NSIs.
Participants will receive the randomized dose of RO7049665 or placebo every 2 weeks 
(Q2W) until they experience relapse or the study is closed (for trial design please refer to 
4.1). Participants will be monitored for at least one hour in the clinical research unit or at 
home after receipt of the first doses administered and receive a follow-up call 8-24 hours 
postdose from the site. To ensure appropriate safety monitoring, the participants will 
receive the first study treatment injections at the clinical research unit. As of week 7,
participants may have the study treatment administered at home by a nurse. If the study 
treatment is administered at the patient’s home, the nurse will stay for an hour after the 
administration.
Furthermore, following the outbreak of coronavirus (COVID-19 or SARS CoV2, declared 
as a global pandemic by the World Health Organization [WHO]), the Sponsor will provide 
the sites with guidance on the reporting of AEs and the capturing of COVID-19 test result
data. There is currently no identified impact of COVID-19 on the data of the ongoing 
study WP40161, or on the known benefit-risk profile of RO7049665.
Overall, the expected benefits of RO7049665 in the treatment of autoimmune conditions 
are greater than the expected risks. The level of risk for participants with AIH is 
considered acceptable as it is mitigated by careful monitoring, careful dose selection, 


RO7049665 — F. Hoffmann-La Roche Ltd
32/Protocol BP42698, Version 2
and study-stopping criteria (Section 4.1.2 and Section 4.1.3). More detailed information 
about the known and expected benefits in the context of potential risks and reasonably 
expected AEs of RO7049665 is provided in the IB.
3.
OBJECTIVES, ENDPOINTS, AND ESTIMANDS
The objectives and corresponding endpoints are provided in Table 5.
Table 5
Objectives and Endpoints
Objectives
Endpoints
Primary

To evaluate the effect of RO7049665 on 
time to relapse following forced CCS
tapering as measured by the hazard ratio 
between 7.5 mg RO7049665 and placebo.

Time to relapse from randomization.
Secondary

To assess changes in alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), and IgG over 
time and by dose.

ALT, AST, and IgG (for both , absolute 
and relative [ULN]) over time.

To evaluate the effect of RO7049665 on 
time to relapse following forced CCS 
tapering as measured by the hazard ratio 
between 3.5 mg RO7049665 and placebo.

Time to relapse from randomization.

To evaluate the safety and tolerability of 
RO7049665 in participants with AIH.

Incidence and severity of adverse events.

Changes in vital signs, physical 
examination, ECG parameters, and safety
laboratory parameters.

ADA emergence and neutralizing 
potential.


RO7049665 — F. Hoffmann-La Roche Ltd
33/Protocol BP42698, Version 2
Tertiary/Exploratory

Assess changes in auto-antibodies.

Titers for anti-nuclear antibodies (ANA), 
and/or anti-smooth muscle antibodies 
(SMA).

Assess changes in patient’s self-reported 
health-related quality of life 

Assess changes in fatigue

Describe health utility state.

Change in health-related quality of life as 
measured by SF-12.

Change in fatigue, as measured by 
PROMIS Fatigue SF 13a scale.

Health utility score as measured by 
EQ-5D-5L.

Assess changes in inflammatory and anti-
inflammatory cytokines.

Inflammatory and anti-inflammatory 
cytokines.

Assess changes in liver histology and 
fibrosis.

Fibroscan®, liver fibrosis markers, liver 
histology.

To assess PD biomarkers (e.g., systemic 
Treg, Teff, Tfh, B cells, sCD25 and in tissue 
as available) and correlate with efficacy 
parameters (modeling and simulation).

For example: Treg, Teff, Tfh and B-cell
counts and sCD25 in peripheral blood and 
tissue as available.

To collect blood samples for measurement 
of RO7049665 serum concentrations.

RO7049665 serum concentrations.
3.1
PRIMARY ESTIMAND
The primary question of scientific interest is “Does administration of RO7049665 to 
participants with confirmed AIH and in stable biochemical remission 2 years (or less if 
according to local clinical practice) and on stable immunosuppressive treatment ≥3 
months prior to randomization (and no dose increase within the previous 6 months
prior to randomization) affect the time to relapse following forced CCS tapering?” The 
following sections describe the components of the corresponding estimand.
For details on the study population, see Section 5.
3.1.1
Treatment
The treatment of interest is treatment with RO7049665. Each dose of RO7049665 used 
in this study will be analyzed separately. Use of prohibited concomitant medications and 
missed doses will be regarded as intercurrent events and will be handled in ways 
described in Section 3.1.3.
3.1.2
Endpoint
The patient-level endpoint that provides information about the question of scientific 
interest is the number of days from randomization to relapse. A participant will be 
considered to have relapsed the first time they meet the criteria given in Section 8.1 at a 


RO7049665 — F. Hoffmann-La Roche Ltd
34/Protocol BP42698, Version 2
post-baseline study visit, whether the visit is scheduled or unscheduled. If the relapse 
requires confirmation at a subsequent visit, the date of relapse will be the date of the first 
set of tests, if confirmed. The sensitivity analyses below will examine the effect of how 
missing confirmatory tests are handled and the impacts on the results of the trial.
3.1.3
Intercurrent Events
The following intercurrent events will be handled using a treatment policy strategy. That 
is, the primary endpoint will be defined to be the earliest of the time to relapse as 
described in Section 8.1 and the time at which any of the events defined below occur.
Table 6
Intercurrent Events and the Statistical Treatment
Permanent discontinuation of study medication unrelated to 
treatment.
Censored
Permanent discontinuation of study medication related to 
treatment.
Estimand event
Temporary discontinuation of study medication regardless of 
relationship to treatment will be discussed by the Sponsor and 
the Investigator to determine whether patient can stay in the 
study and restart treatment (see Section 7.1.1).
In case of 
permanent 
discontinuation, see 
rows 1 and 2.
Initiation of treatment with any systemic CCSs (not related to 
AIH), or any other prohibited concomitant medication listed in 
Section 6.5.2.
Censored
Death due to any cause.
Censored
Liver transplant.
Censored
CCS increase during tapering or reintroduction related to AIH.
Estimand event
In the primary analysis of the primary estimand, participants who experience any of 
these intercurrent events will have a response status as indicated in Table 6 at the time 
of their earliest intercurrent event. Other strategies will be adopted in sensitivity analyses 
(see Section 3.1.5).
Participants who neither relapse nor experience any of the intercurrent events will be 
regarded as censored on the date of their last known follow-up.
3.1.4
Summary Measure
The summary measure used to assess the effect of RO7049665 will be the hazard ratio 
for time to relapse between the relevant RO7049665 group and the SoC group, as 


RO7049665 — F. Hoffmann-La Roche Ltd
35/Protocol BP42698, Version 2
calculated by a Cox proportional hazards model with terms for treatment arm, sex, and 
prednisolone-equivalent CCS dose at baseline. If inclusion of any model term leads to 
model instability, then the terms included in the model may be modified.
3.1.5
Sensitivity Analyses
The most likely cause of “missing” confirmation of relapse is the absence of a 
confirmatory laboratory test results. Therefore, the first sensitivity analysis will define 
relapse to have occurred on the date of the tests that triggered the need for a 
subsequent confirmation, regardless of the result of that confirmation. The status of 
participants whose laboratory test results indicate definitive relapse without the need for 
confirmation will be unchanged. Moreover, if exactly one of the values for ALT or IgG is 
missing at a given visit, this analysis will assume that the missing test meets the criterion 
for retest, and therefore that the participant will have relapsed at that visit.
Additional sensitivity analyses will regard all intercurrent events listed above as relapses 
rather than as censorings and regard all intercurrent events listed above as censorings 
rather than as events.
The fourth and final sensitivity analysis will use multiple imputation to replace any 
missing laboratory test result with values selected at random from other participants in 
the study, matched for sex and prednisolone-equivalent CCS dose. Further details of the 
methodology used will be documented in the study electronic Trial Master File (eTMF).
4.
STUDY DESIGN
4.1
OVERALL DESIGN
An overview of the study design is provided in Section 1.2.
Study BP42698 is a 3-parallel arm (two dose levels of RO7049665 versus placebo), 
randomized, placebo-controlled, double-blind, event-driven, phase 2 study to assess 
efficacy of RO7049665 over placebo in patients with AIH in stable biochemical 
remission. 
Two dose levels will be assessed, 3.5 mg RO7049665 (SC. Q2W) and 7.5 mg 
RO7049665 (SC, Q2W) and matching placebo. 
This is an event-driven study, which means that participants stay in the study and on 
treatment until the participant experiences an event, the necessary number of events is 
reached, the participant stops for other reasons or withdraws consent, or the study ends.
All participants in the study will have been diagnosed with AIH previously and will have 
responded well to treatment with CCSs NSIs. It will be the first attempt to taper out 
CCS completely within the last 3 years (see inclusion criteria Section 5.1). At study 
entry, the disease status of the participants should allow for a stepwise removal of all 


RO7049665 — F. Hoffmann-La Roche Ltd
36/Protocol BP42698, Version 2
immunosuppressive treatment according to local guidelines or practice. If no local 
guidelines exist, EASL guidelines should be applied (EASL 2015: “Treatment should be 
continued for at least three years and for at least 24 months after complete normalisation 
of serum transaminases and IgG levels (biochemical remission). […] In patients with 
continued histological disease activity (HAI >3), immunosuppressive treatment should 
not be discontinued, as relapse is almost certain to occur. […] A trial of treatment 
withdrawal should be undertaken by stepwise reduction of immunosuppressive agents, 
and patients monitored closely.”). Participants will start with study treatment on Day 1 
and start tapering CCS use from Day 8 onwards (see tapering schedule, Section 1.3, 
Table 3) to allow for complete CCS withdrawal within a maximum of 12 weeks, 
depending on the starting dose. Last dose of NSIs, if any, will be taken on Day 1.
Randomization in a 1:1:1 fashion will occur after patient eligibility is confirmed and 
before the first dose of study treatment is administered. Randomization will be stratified 
by equivalent prednisolone dose (7.5 mg daily versus 7.5 mg daily or dual therapy 
[CCS any dose, plus NSI]). 
The study is powered to detect a statistically significant difference between one 
treatment arm and placebo with a sample size of total 84 participants or 28 participants 
per arm after a total of 45 events are observed (see Section 9.2).
Two interim analyses are planned. The first is planned for futility once 25% of events 
(i.e., 12 events) are observed. The second interim analysis for efficacy and futility is 
planned once 50% of events (i.e., 23 events) are observed.
4.1.1
Length of the Study
The study is anticipated to run for approximately 25 months (i.e., 19 months’ recruitment 
and 6 months’ follow-up), until the necessary number of events is observed. If 
recruitment and/or the event rate is faster or slower, then the duration of the study could 
be longer or shorter. It is not possible to estimate the duration of the study for an 
individual patient as this is an event-driven study; the occurrence of an event cannot be 
reliably estimated for an individual patient.
Participants will be monitored for at least one hour in the clinical research unit or at home 
after receipt of the first doses administered and receive a follow-up call 8-24 hours 
postdose from the site. If the study treatment is administered at the patient’s home, the 
nurse will stay for an hour after the administration. To ensure appropriate safety 
monitoring, the participants will receive the first study treatment injections at the clinical 
research unit.
Study periods are divided as follows:

Screening: Up to 28 days.

Treatment period: Day 1 to relapse or final number of events is observed.


RO7049665 — F. Hoffmann-La Roche Ltd
37/Protocol BP42698, Version 2

Safety follow-up: 4 weeks after last administration of study treatment.

End of study visit: Follow-up visit 28 days after last dose of study treatment. In the 
event that a participant is enrolled into an open-label extension (OLE) study, the
follow-up visit will not apply and the last visit within the treatment period will be 
considered as the end of study visit.
4.1.2
Stopping-rules Criteria
The study will stop if either of the interim analyses recommends stopping for success. If 
any interim recommends stopping for futility, the Sponsor’s project team will make the 
actual decision whether to stop or continue the study. This process is mandated by the 
binding nature of the success boundary and the non-binding nature of the futility 
boundary defined in Section 9.2.  Reasons for continuing the study after a futility 
recommendation could include, but are not limited to, an efficacy effect that is smaller 
than assumed in the sample size calculation but still of clinical relevance, or evidence of 
potential benefit not considered in the primary efficacy analysis.
The dosing in the study will be suspended if any of the conditions below occur in 
participants treated with RO7049665:

Clinically manifest secondary (reactive) hypereosinophilia (HER) in 3 participants.

Grade 3 hypersensitivity reaction (as per National Cancer Institute Common 
Terminology Criteria for Adverse Events [NCI-CTCAE] v. 5.0) in 1 participant
considered related to RO7049665.

Local ISRs leading to treatment discontinuation in 5 participants, considered 
related to RO7049665.

ADA with neutralizing potential against endogenous IL-2 in 1 participant.

Other findings (e.g., presence of clinically manifest safety findings in treatment arms 
typically associated with therapeutic IL-2 doses as per aldesleukin label, other AEs 
or lab abnormalities) that, at the joint discretion of the Sponsor’s lead clinical 
scientist and safety science leader, the Sponsor’s IMC and the Investigators, 
indicate that dosing should be stopped.
4.1.3
Individual Stopping Criteria
Dosing will be stopped in a given individual participant if the following circumstances 
occur: 

Grade 3 or greater severe AE or SAE considered related to study treatment, 
including but not limited to:
o
Hypersensitivity reaction which is considered related to study treatment
and believed to pose an unacceptable risk if the dose is repeated.
o
CLS including severe, clinically significant respiratory distress syndrome, 
edema, effusions, or decrease in blood pressure (BP).


RO7049665 — F. Hoffmann-La Roche Ltd
38/Protocol BP42698, Version 2

Grade 3 or higher injection-related reaction (i.e., cytokine release syndrome and 
severe, acute influenza-like syndrome).

Disease relapse signifying study treatment failure (See Section 7).

Other findings that, at the discretion of the Investigator, indicate that dosing should 
be stopped.
Study closure information is provided in Section 4, Appendix 1.
4.1.4
Communication Strategy
The Sponsor and Investigators will be in regular contact throughout the study by 
email/telephone/fax, as per normal interactions during the conduct of a clinical study, 
and the Sponsor will arrange regular teleconferences and meetings to discuss study 
status.
The Sponsor will be available 24 hours a day to discuss any medical or study-related 
issues that may arise during the conduct of this study.
4.1.5
Administrative Structure
In order to keep the study personnel blinded during interim analyses, an Internal 
Monitoring Committee (IMC) will be established.
The unblinded IMC will review the results of each interim analysis and recommend to the 
study team whether the study should stop, continue, or be modified. 
The IMC is a dedicated group of selected Sponsor representatives, who will be 
independent from the project and review the safety and efficacy data of the study, as 
well as the interim analyses. The roles, responsibilities, membership, scope of activities, 
time of meetings, and communication plan for the IMC will be documented in an 
appropriate charter.
4.2
SCIENTIFIC RATIONALE FOR STUDY DESIGN
The study rationale is provided in Section 2.1.
4.2.1
Rationale for Study Population
AIH is a rare and chronic disease without approved treatment. SoC consists of CCSs 
+/- NSIs. Untreated, the disease leads to death within 10 years of diagnosis mainly due 
to liver cirrhosis. Treatment with SoC enables patients with AIH to lead a nearly normal 
life with a normal life expectancy (Heneghan et al 2013).
Nevertheless, lifelong CCS/immunosuppressant treatment poses considerable burden 
on patients with AIH, sometimes with severe side effects like osteoporosis, muscle 
wasting, skin manifestations, and endocrine effects like steroid-induced diabetes
(Heneghan et al 2013).


RO7049665 — F. Hoffmann-La Roche Ltd
39/Protocol BP42698, Version 2
Treatment guidelines (EASL 2015) therefore recommend tapering patients off CCS
treatment and (if possible) other immunosuppressive treatment, in order to relieve 
treatment-related side effects once the patients have reached biochemical remission and 
the liver shows no sign of inflammation. Withdrawal of SoC unfortunately leads more 
often than not to disease relapse (i.e., > 80% as reported by van Gerven et al. 2013). 
Relapsing patients will usually respond again to CCS treatment, require (in most cases)
a higher dose, and have a longer duration to response (van Gerven et al. 2013). After 
the second relapse, it is recommended to keep patients on lifelong immunosuppressive 
treatment.
This study is conducted in patients with AIH currently on immunosuppressive treatment 
prior to their first attempt to taper CCS/NSIs completely within the last 3 years and who
have an unmet medical need for a treatment option beyond CCSs/NSIs.
4.2.2
Rationale for Control Arm
RO7049665 will be compared with placebo, with participants randomized in a 1:1:1 ratio 
to receive one of two doses of RO7049665 or placebo. We will employ a blinded placebo 
arm to derive a preliminary assessment of the efficacy of the different doses of 
RO7049665 in participants with AIH in stable remission and for establishing
drug-relatedness of AEs. A placebo arm will similarly inform the analysis of key 
biomarkers. As we are studying participants with a well-controlled but chronic disease, it 
will be critical to distinguish disease-related complications from intervention associated 
safety signals, as well as study treatment-related changes in leukocyte and cytokine 
biomarkers. In order to get a fair understanding of the efficacy of RO7049665 in AIH, it is 
important to establish the effect over placebo (i.e., to rule out a placebo effect). 
Current EASL treatment guidelines (EASL 2015) propose withdrawal of CCS treatment 
once stable biochemical remission of more than two years without signs of inflammation 
(HAI ≤3) has been achieved in order to remove the risk of CCS-related AEs. There is no 
approved treatment for patients with AIH following withdrawal of CCSs, and RO7049665 
is an investigational drug with no established benefit. Therefore, placebo is an 
appropriate control treatment. Placebo injections are used purely to preserve the blind.
4.2.3
Rationale for Biomarker Assessments 
Key objectives of the mandatory biomarker strategy are to:

confirm and further investigate the expected effect of drug on target cells (expansion 
of Tregs in number) 

identify a safe dose at which the target PD effect can be observed

confirm the magnitude and kinetics of this effect after multiple dosing and in the 
particular study population

correlate a PD effect with clinical outcome


RO7049665 — F. Hoffmann-La Roche Ltd
40/Protocol BP42698, Version 2

characterize the expected target PD effects 

monitor biomarkers for unwanted events such as expansion of effector cells 
(Teff cells, NK cells, and eosinophils) 
These assessments are expected to add valuable information towards an estimate of the 
therapeutic window, patient selection, and prediction of clinical response. 
Additional objectives of the mandatory biomarker assessments are: (1) to investigate if 
systemic PD effects can be measured as surrogate markers for predicting relapse; (2) to 
identify which of the candidate systemic biomarkers shows highest correlation to tissue 
effects (as available); (3) to determine if any systemic or tissue biomarkers can predict 
efficacy.
A fresh or historical liver biopsy is required before randomization. Provided no worsening 
of disease has occurred, a historical biopsy taken no more than 12 months prior to 
randomization is acceptable. A formalin-fixed paraffin embedded (FFPE) block has to be 
sent to the Sponsor if available. It will be used to characterize immune cell infiltration and 
histologic appearance. Additional measurements which may be performed on liver 
biopsy-derived material are whole (spatial) transcriptome or targeted gene expression 
analyses. An optional liver biopsy at 6 months of treatment will provide the opportunity to 
assess changes in tissue markers from baseline. The objective of these measurements 
is to confirm the translation of changes in T cell subsets from blood to tissue and to 
identify further mechanistic markers such as changes in inflammatory signatures or 
markers of tissue healing.
Blood samples will be collected to quantify relative and absolute WBC counts (including 
B cells, T cells, NK cells, and eosinophils). Furthermore, markers for quantification and 
characterization of Tregs and Teff subsets including, but not limited to CD3, CD4, CD8, 
CD127, CD25, and FoxP3 will be determined. 
Serum and plasma samples will be collected to measure cytokines or other soluble 
biomarkers mechanistically linked to RO7049665’s mode of action or the disease. In 
addition, exploratory safety biomarkers may be measured in an ad-hoc fashion, (e.g., in 
participants experiencing symptoms associated with injection-related reactions).
Clinical blood genotyping data may be used to explore whether genotype may correlate 
with efficacy, influence the magnitude of PD effects, or impact the safety of RO7049665. 
Exploratory disease biomarkers in serum samples will be tested for their ability to stratify 
participants and to evaluate their potential for non-invasive response to treatment 
monitoring.
Additional PD biomarkers and methods to obtain further confidence on the mechanism 
of action of RO7049665 in participants may be tested. Such assessments may include, 
but are not limited to, determining specific methylation signatures in blood or liver


RO7049665 — F. Hoffmann-La Roche Ltd
41/Protocol BP42698, Version 2
biopsies to quantify Treg or Teff subsets and possibly the functionality of such. The 
purpose of this assessment is to explore alternative T cell subset quantification methods 
and to understand their potential usefulness for replacing established methods with 
limited throughput and logistical challenges in later stages of clinical development.
4.3
JUSTIFICATION FOR DOSE
The doses are based on data from the EIH study (WP39826) in healthy volunteers and 
the ongoing MAD WP40161 study in participants with UC. The therapeutic range of 
RO7049665 is unknown; however, the estimated therapeutic range of Treg was achieved 
with the doses of 2200 µg, 5000 µg, and 7500 µg, eliciting a mean increase of 2-, 4-, and 
6-fold, respectively, as compared with baseline without stimulating expansion of effector 
T cells (Teff ; see the RO7049665 Investigator Brochure). In AIH, the intrahepatic Treg/Teff 
ratio appears to be a determinant of disease progression, because patients reaching 
biochemical remission have higher intrahepatic Treg/CD8 and Treg/B cell ratios, whereas 
this ratio remains constant in the liver of untreated patients with AIH (Taubert et al. 
2014). Also, the disproportional decrease of intrahepatic Treg during SoC 
immunosuppressive therapy might explain the high relapse rates after discontinuation of 
immunosuppression. Thus, intrahepatic immunoregulation through Treg expansion may
be better suited for long-term control of AIH.
Data from WP39826 demonstrated 4-fold expansion of Treg cells in healthy volunteers 
after a single 5-mg dose of RO7049665 (mean peak Treg expansion to 155.2 cells/L) 
and a mean 5.8-fold expansion of Treg cells after a single 7.5-mg dose (with a mean peak 
of approximately 200 cells/L [range 123 – 297]). The 2.2 mg single dose in the SAD 
study elicited a mean 2-fold increase in Treg cells; therefore, the lower dose of 3.5 mg in 
Study BP42698 is expected to produce a measurable PD effect (specifically, the 
expansion of Treg cells), but the overall expansion is projected to be at the lower end of 
the hypothesized therapeutic target.
Single doses at these dose levels were safe and well tolerated in healthy volunteers with 
no SAEs and no DLAEs, with limited expansion of Teff and eosinophils and no observed 
effect on NK cells. The maximum Treg expansion was observed at Day 8 following 
dosing. Similar results could be preliminarily confirmed in the MAD study WP40161. 
Further details are provided in the RO7049665 Investigator’s Brochure.
4.4
END OF STUDY DEFINITION
The goal of the study is achieved when any of the interim analyses results in a decision 
to stop the study, when the required number of events is reached, or if any of the 
stopping rules apply. At this point, the study will be unblinded.
An individual participant has completed the study if he/she has completed all scheduled 
procedures as shown in the SoA (see Section 1.3).


RO7049665 — F. Hoffmann-La Roche Ltd
42/Protocol BP42698, Version 2
The end of the study is defined as the date when the last participant last observation 
(LPLO) occurs. LPLO is expected to occur approximately 4 weeks after study closure 
when the final follow-up visit is conducted. Study closure can occur either after:

The first interim analysis for futility, or

The second interim analysis for futility or efficacy, or

45 events are observed, or

Early study termination.
The Sponsor may set up an OLE study if RO7049665 development continues. 
Participants not having had a relapse at study closure may have the option to enter the 
OLE study. For participants entering a possibly available OLE study, the last regular visit 
will count as last observation in Study BP42698. Participants not entering the OLE study 
will have a last observation 4 weeks after the last dose of RO7049665 or placebo.
5.
STUDY POPULATION
The study population rationale is provided in Section 4.2.1.
The participants of this study are patients with biopsy-proven diagnosis of AIH, with no 
evidence of cirrhosis with significant impairment of liver function stage (e.g., Child Pugh 
B or C). Patients must be in biochemical remission for at least 2 years (or less if 
according to the local practice), be on stable treatment (CCSs NSIs) for at least 3
months prior to randomization (and who have not had a dose increase 6 months prior to 
randomization), and show no signs of inflammation (HAI ≤3) on a liver biopsy taken no 
more than 12 months prior to randomization.
This study will recruit approximately 84 female and male participants diagnosed with AIH 
who are between 18 and 75 years of age, inclusive, and satisfy all of the inclusion and 
exclusion criteria.
Prospective approval of protocol deviations, also known as protocol waivers or 
exemptions, is not permitted.
5.1
INCLUSION CRITERIA
Participants are eligible to be included in the study only if all of the following criteria 
apply:
Informed Consent
1.
Able and willing to provide written informed consent and to comply with the study 
protocol according to International Conference on Harmonisation (ICH) and local 
regulations.


RO7049665 — F. Hoffmann-La Roche Ltd
43/Protocol BP42698, Version 2
Age
2.
Between 18 to 75 years of age, inclusive, at the time of signing the informed 
consent.
Type of Participants and Disease Characteristics
3.
Patients with a definite diagnosis of AIH (type 1, 2 and 3) as per simplified or revised 
original diagnostic criteria (including response to CCSs) (Hennes et al 2008). 
4.
Patients who have been in biochemical remission (complete normalization of serum 
transaminases and IgG levels [if IgG is measured, as according to local practice]) 
for 2 years (or less if according to the local practice) prior to randomization. At
least two measurements of IgG levels within normal range at least two weeks apart
need to be available before randomization. 
5.
Patients who have been on stable treatment (CCSs NSIs) for at least 3 months 
prior to randomization and who have not had a dose increase in the previous 6 
months prior to randomization.
6.
No signs of liver inflammation (HAI 3) on a liver biopsy taken no more than 
12 months prior to randomization.
7.
Patients with AIH who have previously not attempted (or not attempted in the last 3
years, if this is the local practice) to taper CCS to 0 mg/day.
Weight
8.
Body mass index (BMI) within the range of 18-35 kg/m2 (inclusive).
Sex and Contraception/Barrier Requirements
9.
Male and female participants are eligible.
The contraception and abstinence requirements are intended to prevent exposure of 
an embryo to the study treatment. Therefore, the reliability of sexual abstinence for 
female enrollment eligibility needs to be evaluated in relation to the duration of the 
clinical study and the preferred and usual lifestyle of the participant. Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) 
and withdrawal are not acceptable methods of preventing drug exposure.
A female participant is only eligible to participate if she is not pregnant, not 
breastfeeding, and at least one of the following conditions applies:

Women of non-childbearing potential (WONCBP),
OR

Women of childbearing potential (WOCBP), who:
Agree to remain abstinent (refrain from heterosexual intercourse) or use at least one 
acceptable contraceptive method during the treatment period and for at least 
28 days after the final dose of study treatment. 


RO7049665 — F. Hoffmann-La Roche Ltd
44/Protocol BP42698, Version 2
The following are acceptable contraceptive methods: bilateral tubal occlusion/ 
ligation, male sexual partner who is sterilized, established proper use of hormonal 
contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and 
copper intrauterine devices, male or female condom with or without spermicide; and 
cap, diaphragm, or sponge with spermicide (see Appendix 5).
5.2
EXCLUSION CRITERIA
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1.
Patients with cirrhosis (F4 fibrosis by Fibroscan®) with significant impairment of liver 
function (Child Pugh category B or C).
2.
Any other autoimmune disease (including overlap syndrome) requiring 
immunomodulating treatment.
3.
History of infection with hepatitis B (HBsAg positive and/or anti-HBc positive; HBV 
vaccinated patients are eligible), human immunodeficiency virus (HIV; positive HIV 
antibody test), active hepatitis C virus (HCV) infection (detectable HCV RNA),
detection of replicating CMV or Epstein-Barr virus (EBV).
4.
Active infections requiring systemic therapy with antibiotic, antiviral, or antifungal
treatment or febrile illness within 7 days before Day 1.
5.
History of primary or acquired immunodeficiency.
6.
Female patients: Pregnant or lactating.
7.
Symptomatic herpes zoster within 3 months prior to screening.
8.
History of active or latent tuberculosis or a positive QuantiferonGold test.
9.
History of clinically significant severe drug allergies, multiple drug allergies, allergy 
to any constituent of the product, or intolerance to topical steroids.
10. Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal 
cell or squamous epithelial carcinomas of the skin that have been resected with no 
evidence of metastatic disease for 3 years and in situ carcinoma of the cervix that 
was completely removed surgically. Breast cancer within the past 10 years.
11. Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart
failure New York Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic,
endocrine, or gastrointestinal disorders (excluding UC).
12. Any condition or disease detected during the medical interview/physical examination 
that would render the patient unsuitable for the study, place the patient at undue 
risk, or interfere with the ability of the patient to complete the study in the opinion of 
the Investigator.


RO7049665 — F. Hoffmann-La Roche Ltd
45/Protocol BP42698, Version 2
Prior/Concomitant Therapy
13. CCSs of 5 mg/day (prednisolone-equivalent dose), or < 2.5 mg CCSs 
(prednisolone-equivalent dose) plus immune suppressant, or < 3 mg/day 
budesonide with or without immune suppressant.
14. CCSs 20 mg/day (prednisolone-equivalent dose) or > 9 mg/day budesonide.
15. NSI daily dose higher than recommended standard of care therapy.
16. T or B cell-depleting therapy (e.g., rituximab) within the last 12 months or T- or 
B-cell number below normal due to depleting therapy.
Prior/Concurrent Clinical Study Experience
17. Leukocyte apheresis within 12 weeks of screening.
18. Donation of blood or blood products in excess of 500 mL within 3 months prior to 
screening.
19. Exposure to any investigational treatment within 6 months prior to Day 1.
Laboratory Abnormalities
20. Abnormal hematologic values:

Anemia (hemoglobin 9 g/dL)

Leukocytosis (white blood cells 2 upper limit of normal [ULN])

Thrombocytopenia (platelet count 100,000/L)

Thrombocytosis (platelet count 2 ULN)

Eosinophilia (eosinophil count 2 ULN)
21. Abnormal hepatic enzyme or hepatic function values:

ALT, AST, or alkaline phosphatase, above normal range

Total bilirubin 2 ULN

International normalized ratio (INR) 1.7

Albumin 3 g/dL
22. Abnormal biochemistry values:

IgG above normal range
Other Exclusions
23. History of regular alcohol consumption within 2 months of screening defined as:
An average weekly intake of 14 drinks for men or 7 drinks for women. One drink 
is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of 
wine, or 1.5 ounces (45 mL) of 80 proof distilled spirits (equivalent to 40 vol%).
24. Any suspicion or history of illicit drug use.


RO7049665 — F. Hoffmann-La Roche Ltd
46/Protocol BP42698, Version 2
25. Patients under judicial supervision, guardianship, or curatorship.
5.3
LIFESTYLE CONSIDERATIONS
This section is not applicable for this study.
5.4
SCREEN FAILURES
Screen failures are defined as participants who consent to participate in the study but 
are not subsequently randomized to study treatment/entered in the study. Screen 
failures may be tracked separately.
The Investigator will maintain a screening log to record details of all participants 
screened and to confirm eligibility or record reasons for screening failure.
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be re-screened up to three times if it is thought that the reason for failure is transient in 
nature. 
Re-screened participants should be assigned the same participant number as for the 
initial screening. 
For re-screened participants, the following specific criteria must be met:

Results of a liver biopsy taken within 12 months of randomization must be available
(see criteria for biopsy under Section 4.2.3).

Testing for HBV, HIV, HCV, CMV, and EBV and latent tuberculosis infection need 
not be repeated if they have been already done within 6 months and their results 
were negative. 

WOCBP must repeat pregnancy testing.

Screening laboratory evaluations beyond those itemized above must be completed 
within 28 days of the first dosing. 
6.
TREATMENTS
Study intervention is defined as any investigational product (including placebo) or 
marketed product intended to be administered to a study participant according to the 
study protocol.
The investigational medicinal products (IMPs) for this study are RO7049665 or matching 
placebo. All IMPs required for completion of this study will be provided by the Sponsor.
The first three doses of study treatment will be administered by the investigational staff 
(i.e., Investigator or study nurse) at the study center under supervision of the 
Investigator. Administration of study treatment should be done in the abdomen. Once the 
safe administration of study treatment is confirmed, it is at the discretion of the 


RO7049665 — F. Hoffmann-La Roche Ltd
47/Protocol BP42698, Version 2
Investigator whether to allow administration of study treatment at the participant’s home 
by a home nurse.
Corticosteroids are considered non-investigational medicinal products (NIMPs).
Cases of overdose and medication error, along with any associated AEs, have to be 
reported as described in Section 5.2, Appendix 2.
6.1
TREATMENTS ADMINISTERED
The treatments administered are summarized in Table 7. Guidelines for dosage 
modification and treatment interruption or discontinuation are provided in Section 6.6 or 
Section 7, respectively.
Please see the IB(s) and pharmacy manual for more details. 
Table 7
Summary of Treatments Administered
Study Treatment 
Name:
RO7049665
Placebo
IMP and NIMP:
IMP
IMP
Dosage Formulation:
Solution for injection
Solution for injection
Unit Dose Strength:
5.0 mg/mL
N/A
Dose:
3.5 mg or 7.5 mg
N/A
Route of 
Administration:
SC injection
SC injection
Dosing Instructions:
RO7049665 must be prepared 
for dosing under appropriate 
aseptic conditions and should 
be used immediately. The
solution for injection must be 
filtered prior to use.
Placebo must be prepared for 
dosing under appropriate 
aseptic conditions and should 
be used immediately. The
solution for injection must be 
filtered prior to use.
Packaging and 
Labeling:
RO7049665 and placebo will be provided in 2 mL colorless glass 
vials. Each vial will be labeled as required per country 
requirement.
Storage Conditions:
For RO7049665 and placebo, if not used immediately, the total 
storage time of the dose solution prior to administration should not 
exceed 24 hours to limit the risk of microbial growth in case of 
accidental contamination. The recommended storage condition for 
the dose solution is 2C to 8C, protect from light, but dose 
solutions may be stored at room temperature for up to a maximum 
of 4 hours.
Manufacturer:
F. Hoffmann-La Roche, Ltd.
F. Hoffmann-La Roche, Ltd.


RO7049665 — F. Hoffmann-La Roche Ltd
48/Protocol BP42698, Version 2
6.2
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY
Study treatment packaging will be overseen by the Sponsor’s clinical study supplies 
department and bear a label with the identification required by local law, the protocol 
number, drug identification and dosage.
The packaging and labeling of the study medication will be in accordance with the 
Sponsor’s standard and local regulations.
The study site should follow all instructions included with each shipment of IMP. The 
investigational site will acknowledge receipt of IMPs and confirm the shipment condition 
and content. Any damaged shipments will be replaced. The Investigator or designee 
must confirm that appropriate temperature conditions have been maintained during 
transit for all IMPs received and that any discrepancies have been reported and resolved 
before use of the IMPs. All IMPs must be stored in a secure, environmentally controlled, 
and monitored (manual or automated) area in accordance with the labeled storage 
conditions, with access limited to the Investigator and authorized staff.
Only participants enrolled in the study may receive IMPs, and only authorized staff may 
supply or administer IMPs.
The study site (i.e., Investigator or other authorized personnel [e.g., pharmacist or home 
nurse]) is responsible for maintaining records of IMP delivery to the site, IMP inventory at 
the site, IMP use by each patient, and disposition or return of unused IMP, thus enabling 
reconciliation of all IMP received, and for ensuring that participants are provided with 
doses specified by the protocol. Upon arrival of the IMPs at the site, site personnel will 
complete the following:

Check the IMPs for damage.

Verify proper identity, quantity, integrity of seals and temperature conditions.

Report any deviations or product complaints to the Study Monitor upon discovery.
The qualified individual responsible for dispensing the study treatment will prepare the 
correct dose according to Interactive Voice/Web Response System (IxRS) and 
Pharmacy Manual.
The Investigator or delegate must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and any discrepancies are 
reported and resolved before use of the study treatment.
Only participants enrolled in the study may receive study treatment and only authorized 
staff may supply or administer study treatment. All study treatments must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the Investigator 
and authorized staff.


RO7049665 — F. Hoffmann-La Roche Ltd
49/Protocol BP42698, Version 2
The Investigator is responsible for study treatment accountability, reconciliation, and 
record maintenance (i.e., receipt, reconciliation, and final disposition records).
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or returned to the Sponsor with the appropriate 
documentation. The site's method of IMP destruction must be agreed upon by the 
Sponsor. Local or institutional regulations may require immediate destruction of used 
IMP for safety reasons. The site must obtain written authorization from the Sponsor 
before any IMP is destroyed, and IMP destruction must be documented on the 
appropriate form. Accurate records of all IMPs received at, dispensed from, returned to, 
and disposed of by the study site should be recorded on the drug accountability log.
Refer to the pharmacy manual and RO7049665 Investigator’s Brochure for information
on IMP formulation, IMP handling, including preparation and storage, and accountability.
6.3
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND 
BLINDING
6.3.1
Method of Treatment Assignment
Randomization will occur once all eligibility criteria have been satisfied, and time to event 
will be measured in days from the date of randomization. The randomization will be 
stratified as described in Section 4.1.
All participants will be centrally assigned to randomized study treatment using an IxRS. 
Before the study is initiated, the telephone number and call-in directions for the IxRS 
and/or the login information and directions for the IxRS will be provided to each site.
The randomization numbers will be generated by the Sponsor or its designee. The 
randomization list will be made available to the individual responsible for PK/PD sample 
bioanalysis, and to statisticians or programmers at Roche. PK/PD data can be received 
and cleaned on an ongoing basis. The data will be handled and cleaned in a restricted
area which is not accessible by any blinded study management team member.
Study treatment will be administered at the study visits indicated in the SoA
(Section 1.3). 
6.3.2
Blinding
Interim analyses will be conducted by a group independent of the study team and 
decisions flowing from the results of the interim analyses will be communicated in a 
blinded fashion.
PK/PD data can be received and cleaned on an ongoing basis. The data will be handled 
and cleaned in a restricted area which is not accessible by any blinded study 
management team member. 


RO7049665 — F. Hoffmann-La Roche Ltd
50/Protocol BP42698, Version 2
If unblinding is necessary for participant management (in the case of an SAE), the 
Investigator will be able to break the treatment code by contacting the IxRS. Treatment 
codes should not be broken except in emergency situations. If the Investigator wishes to 
know the identity of the study treatment for any other reason, he/she should contact the 
Medical Monitor directly. The Investigator should document and provide an explanation 
for any premature unblinding (e.g., accidental unblinding, unblinding due to a SAE).
The randomization schedule will not be made available to any member of the core study 
team. The randomization schedule may be made available to members of the extended 
study team on the basis of operational need. Reasons for providing access to the 
randomization list include, but is not limited to, support for the functions of the IMC and
PK. The names and responsibilities of all those to whom the randomization schedule is 
released will be documented in the eTMF along with the date of release. As per Health 
Authority reporting requirements, the Sponsor will break the treatment code for all 
unexpected SAEs (see Section 8.3.4) that are considered by the Investigator to be 
related to study treatment.
6.4
TREATMENT COMPLIANCE
The qualified individual responsible for dispensing the study treatment will prepare the 
correct dose according to the randomization schedule. This individual will write the date 
dispensed and participant number on the study treatment vial label and on the Drug 
Accountability Record. This individual will also record the study treatment number 
received by each participant during the study.
6.5
CONCOMITANT THERAPY
In case participants experience a relapse of their disease (see Table 8, Section 8.1) 
treatment, mainly high dose CCS and/or other NSIs, may be provided by the study site.
Participants who experience an AE will be followed up for safety (see Section 8.3.1). 
6.5.1
Permitted Therapy
Any medication (including over-the-counter [OTC] or prescription medicines, approved 
dietary and herbal supplements, nutritional supplements) used by a participant from 
30 days prior to screening until the follow-up visit must be recorded along with reason for 
use, dates of administration (including start and end dates) and dosage information 
(including dose and frequency). 
The same information must be recorded in the eCRF for the following concomitant 
medications taken by a participant during the indicated period prior to screening until the 
follow-up visit:

CCSs and NSIs (e.g., AZA, 6-MP, MMF) used 12 months prior to randomization.


RO7049665 — F. Hoffmann-La Roche Ltd
51/Protocol BP42698, Version 2

Pre-medication for the management injection-related reactions (e.g., 
anti-histamines).

Ursodeoxycholic acid (UDCA).
The Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.
All therapy and/or medication administered to manage AEs should be recorded on the 
Adverse Event eCRF.

Participants who use the following therapies prior to screening and are on a stable 
regimen should continue their use: 
o
Oral contraceptives, 
o
Hormone-replacement therapy,
o
UDCA,
o
Maintenance therapy for concomitant diseases.

Participants will taper their CCS therapy for AIH during the first weeks of the study 
according to the SoA table (see Section 1.3, Table 3).
6.5.2
Prohibited Therapy
As a general rule, no concomitant medication to treat the underlying disease other than 
CCSs during tapering will be permitted. 
Use of the following therapies will be prohibited during the study:

CCS after tapering has been completed, except topical steroids.

Any other immune system targeted biological therapy (including but not limited to 
JAK inhibitors).
6.6
DOSE MODIFICATION
No dosage modification of RO7049665 is permitted for any participant in the study.
Study treatment may be temporarily halted and restarted, as described in Sections 7.1.1.
6.7
TREATMENT AFTER THE END OF THE STUDY
Currently, the Sponsor does not commit to provide study treatment or other study 
interventions to participants after conclusion of the study or any earlier participant 
withdrawal. The Sponsor will evaluate the appropriateness of continuing to provide study 
treatment to participants after evaluating the primary efficacy outcome measure and 
safety data gathered in the study; these analyses may be conducted prior to completion 
of the study. If these data are medically significant, the Sponsor may decide to open an 
OLE study to participants. This OLE study might continue until study treatment is 


RO7049665 — F. Hoffmann-La Roche Ltd
52/Protocol BP42698, Version 2
commercially available to the participating participants in their countries, or until the 
Sponsor ceases producing or studying the study treatment.
7.
DISCONTINUATION OF STUDY, STUDY TREATMENT, AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL
An excessive rate of withdrawals (either participants discontinuing study treatment or 
withdrawing from the study) can render the study non-interpretable. Therefore, 
unnecessary withdrawal of participants should be avoided and efforts should be taken to 
motivate participants to comply with all the study-specific procedures as outlined in this 
protocol.
Details on study and site closures are provided in Appendix 1 Study Governance 
Considerations Study.
7.1
DISCONTINUATION OF STUDY TREATMENT
For data to be collected at the time of treatment discontinuation and follow-up and for 
any further evaluations that need to be completed see the SoA (Section 1.3).
Reasons for discontinuation of study treatment (or withdrawal from the study) may 
include, but are not limited to, the following:

Participant withdrawal of consent at any time.

Any medical condition that the Investigator or Sponsor determines may jeopardize 
the participant’s safety if he or she continues in the study.

Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the participant.

Pregnancy.

Disease relapse (See Section 8.1).

Any event that meets stopping criteria defined in Section 4.1.3.
Every effort should be made to obtain information on participants who withdraw from the 
study but have not withdrawn consent. Participants who discontinue study treatment 
prematurely will be asked to return to the clinic for a study completion/early termination 
visit (see Section 8.11.3) and may undergo follow‑up assessments (see Section 8.11.4), 
unless the participant withdrew consent. The primary reason for premature study 
treatment discontinuation should be documented on the appropriate eCRF. Participants 
who discontinue study treatment prematurely will not be replaced.
7.1.1
Temporary Interruption
Before permanently discontinuing study treatment (regardless of whether initiated by the 
participant, the Investigator or Sponsor), an interruption should be considered. 
Participants who have had study treatment temporarily interrupted should be considered 


RO7049665 — F. Hoffmann-La Roche Ltd
53/Protocol BP42698, Version 2
to restart as soon as medically justified in the opinion of the Investigator after discussion 
with the Sponsor. If more than one study treatment administration throughout the study 
is omitted, restarting administration needs to be discussed and agreed with the Sponsor.
If RO7049665 administration is delayed by more than 7 days from the schedule 
administration date, the dose will then be considered a missed dose. Administration may 
resume at the next planned dosing date. A missed dose of RO7049665 will not be made 
up.
A dosing delay of 2 days (e.g., due to holidays or bad weather conditions) after the 
fourth dosing will not be counted as a protocol violation.
When study treatment is paused, assessments will continue as per SoA, if possible (see 
Section 1.3).
7.2
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE 
STUDY
Participants have the right to voluntarily withdraw from the study at any time for any 
reason.
In addition, the Investigator has the right to withdraw a participant from the study for 
medical conditions that the Investigator or Sponsor determines may jeopardize the 
participant’s safety if he/she continues in the study.
If possible, information on reason for withdrawal from the study should be obtained. The 
primary reason for withdrawal from the study should be documented on the appropriate 
eCRF. Participants will not be followed for any reason after consent has been withdrawn.
When a participant voluntarily withdraws from the study, or is withdrawn by the 
Investigator, samples collected until the date of withdrawal will be analyzed, unless the 
participant specifically requests for these to be discarded or local laws require their 
immediate destruction. However, if samples have been tested prior to withdrawal, results 
from those tests will be used as part of the overall research data. A participant's 
withdrawal from this study does not, by itself, constitute withdrawal of samples donated 
to the Research Biosample Repository (RBR).
Participants who withdraw from the study for safety reasons will not be replaced. 
Participants who withdraw from the study for other reasons will not be replaced.
For data to be collected at the time of study discontinuation and at safety and follow-up 
visits, and for any further evaluations that need to be completed see SoA (Section 1.3).


RO7049665 — F. Hoffmann-La Roche Ltd
54/Protocol BP42698, Version 2
7.3
LOST TO FOLLOW-UP
A participant will be considered lost to follow-up if the participant repeatedly fails to 
return for scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a 
required study visit:

The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study.

Before a participant is deemed lost to follow-up, the Investigator or designee must 
make every effort to regain contact with the participant. These contact attempts 
should be documented in the participant’s medical record.

Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study.
Discontinuation of sites or of study as a whole are handled as part of Appendix 1.
8.
STUDY ASSESSMENTS AND PROCEDURES
Study procedures and their timepoints are summarized in the SoA (Section 1.3). 
Protocol waivers or exemptions are not allowed.
Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study treatment.
Procedures conducted as part of the participant’s routine clinical management (e.g.,
blood count) and obtained before signing of the Informed Consent Form (ICF) may be 
utilized for screening or baseline purposes provided that the procedure met the 
protocol-specified criteria and was performed within the time-frame defined in the SoA
(Section 1.3).
Samples for laboratory tests will be sent to one or several central laboratories or to the 
Sponsor for analysis. Instruction manuals and supply kits will be provided for all central 
laboratory assessments.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.
Based on continuous analysis of the data in this study, any assessment, sample type, or 
biomarker evaluation not considered to be critical for safety may be stopped at any time 
if the data from the assessments or samples collected does not produce useful 
information.




RO7049665 — F. Hoffmann-La Roche Ltd
56/Protocol BP42698, Version 2
EQ-5D Questionnaire
The EuroQol 5-Dimension Questionnaire 5-level version (EQ-5D-5L; see Appendix 6) is 
a self-reported health status questionnaire that consists of six questions used to 
calculate a health utility score for use in health economic analysis (EuroQol Group 1990; 
Brooks 1996; Herdman et al 2011; Janssen et al 2013). There are two components to 
the EuroQol EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression, as well as a visual analogue 
scale (VAS) that measures health state. Published weighing systems allow for creation 
of a single summary score. Overall, scores range from 0 to 1, with low scores 
representing a higher level of dysfunction. The EQ-5D-5L will be utilized in this study for 
economic modeling.
SF-12v2
The SF-12v2 (see Appendix 6) will be used to assess patient’s health-related quality of 
life (QoL) (Ware et al. 1996).
The 12-item questionnaire consists of eight domains: 

Physical functioning (2 items) 

Role-physical (2 items) 

Bodily pain (1 item) 

General health (1 item) 

Vitality (1 item) 

Social functioning (1 item) 

Role-emotional (2 items) 

Mental health (2 items) 
The SF-12v2 has a recall specification of 4 weeks, and items are assessed on 3- to 
5-point Likert scales. A higher score indicates better health. The SF-12v2 health survey 
will be used in this study to assess health-related QoL and for economic modeling.
PROMIS Fatigue – Short Form 13a (FACIT-Fatigue) 
The FACIT-Fatigue is a 13-item scale developed as a measure of fatigue with a recall 
period of the preceding 7 days. 
Items are assessed on a 5-point Likert scale, with responses ranging from 1 “not at all” 
to 5 “very much.” The total raw score is the sum of the values of each scored question
and ranges from 13 to 65. Scores will also be transformed to a PROMIS T-score that 
has been calibrated so that a score of 50 is comparable to the “average” fatigue in the 
general population and a standard deviation of 10. The T-scores range from 30.3 to 83.5 
with a higher score being associated with worse fatigue (scoring manual; see 
Appendix 6).


RO7049665 — F. Hoffmann-La Roche Ltd
57/Protocol BP42698, Version 2
During clinic visits, COA instruments should be administered as outlined below:

Participants' health status should not be discussed prior to administration of the 
instruments.

Sites must administer the official version of each instrument, as provided by the 
Sponsor. Instruments must not be copied from the protocol.

Sites should allow sufficient time for participants to complete the instruments.

Sites should administer the instruments in a quiet area with minimal distractions and 
disruptions.

Participants should be instructed to answer questions to the best of their ability; 
there are no right or wrong answers.

Site staff should not interpret or explain questions but may read questions verbatim 
upon request.

Participants should not obtain advice or help from others (e.g., family members or 
friends) when completing the instruments.
8.2
SAFETY ASSESSMENTS
Planned timepoints for all safety assessments are provided in the SoA (Section 1.3).
Safety assessments will consist of monitoring and recording AEs, including SAEs and 
non-serious AEs of special interest (NSAESI); measurement of protocol-specified safety 
laboratory assessments; measurement of protocol-specified vital signs, ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study.
8.2.1
Physical Examinations
A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and 
musculoskeletal systems; in addition to head; eyes; ears; nose; throat; neck; and lymph 
node systems. Height and weight will also be measured and recorded. Further 
examination of other body systems may be performed at the Investigator’s discretion.
An abbreviated physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal, dermatological, and neurological systems;
and measurement of body weight. 
A complete or abbreviated physical examination will be performed at the timepoints 
specified in the SoA (Section 1.3) by trained medical personnel at the study center. 
Attention should be paid to signs and symptoms suggestive of type 3 hypersensitivity 
reactions.
The BMI will be calculated. Height will be recorded at screening only. Body weight will be 
recorded at screening and at all subsequent physical examinations and as clinically 
indicated.


RO7049665 — F. Hoffmann-La Roche Ltd
58/Protocol BP42698, Version 2
Any abnormality identified at baseline should be recorded on the General Medical 
History and Baseline Conditions eCRF.
Changes from baseline abnormalities should be recorded in participant’s notes. New or 
worsened clinically significant abnormalities should be recorded as AEs on the Adverse 
Event eCRF.
8.2.2
Vital Signs
BP, pulse rate, body temperature (forehead, tympanic or oral) and respiratory rate will be 
assessed at the timepoints specified in the SoA (Section 1.3).
BP and pulse measurements will be assessed in a supine position with a completely 
automated device. Manual techniques will be used only if an automated device is not 
available. When possible, the same arm should be used for all BP measurements.
BP and pulse measurements should be preceded by at least 5 minutes of rest for the 
participant in a quiet setting without distractions (e.g., television, cell phones).
Three readings of BP and pulse will be taken. The first reading should be rejected. The 
second and third readings should be averaged to give the measurement to be recorded 
in the eCRF.
Single measurements of the other vital signs will be taken before blood collection for 
laboratory tests but after ECG collection when scheduled at the same timepoint.
The timings of assessments may be amended or the number of assessments increased 
during study conduct on the basis of emerging data in order to allow for optimal 
characterization of the effect profile.
8.2.3
Electrocardiograms
Triplicate 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using an 
ECG machine. Measurements of PR, QRS complex (QRS), QT, and QTc intervals may 
be performed by the instrument or calculated using an external tool. 
At each timepoint at which triplicate ECGs are required, three individual ECG tracings 
should be obtained as closely as possible in succession but no more than 5 minutes 
apart. The full set of triplicates should be completed in less than 10 minutes.
To minimize variability, it is important that participants be in a resting position for 
10 minutes prior to each ECG evaluation. Body position should be consistently 
maintained for each ECG evaluation to prevent changes in heart rate. Environmental 
distractions (e.g., television, radio, conversation) should be avoided during the pre-ECG 
resting period and during ECG recording. ECGs should be performed prior to any 
scheduled vital sign measurements and blood draws. In some cases, it may be 


RO7049665 — F. Hoffmann-La Roche Ltd
59/Protocol BP42698, Version 2
appropriate to repeat abnormal ECGs to rule out improper lead placement as 
contributing to the ECG abnormality. 
For safety monitoring purposes, the Investigator or designee must review, sign, and date 
all ECG tracings. Paper or electronic copies will be kept as part of the participant’s 
permanent study file at the site. If considered appropriate by Roche, ECGs may be 
analyzed retrospectively at a central laboratory.
ECG characteristics (including heart rate, QRS duration, and PR, and QT intervals) will 
be recorded on the eCRF. QTcF (Fridericia’s correction) and RR will be calculated and 
recorded on the eCRF. Changes in T‑wave and U‑wave morphology and overall ECG 
interpretation will be documented on the eCRF. T-wave information will be captured as 
normal or abnormal, U-wave information will be captured in two categories: 
absent/normal or abnormal.
8.2.4
Clinical Safety Laboratory Assessments
Normal ranges for the study laboratory parameters must be supplied to the Sponsor 
before the study starts. A list of clinical laboratory tests to be performed is provided in 
Appendix 4 and these assessments must be conducted in accordance with the separate 
laboratory manual and the SoA (Section 1.3).
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant 
abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by the Investigator to be more severe than expected for the 
participant's condition.

In the event of unexplained abnormal clinically significant laboratory test values, the 
tests should be repeated immediately and followed up until they have returned to 
the normal range and/or an adequate explanation of the abnormality is found.

If such values do not return to normal/baseline within a period of time judged 
reasonable by the Investigator, the etiology should be identified and the Sponsor 
notified.

If laboratory values from non-protocol-specified laboratory assessments performed 
at the local laboratory require a change in participant management or are 
considered clinically significant by the Investigator (e.g., SAE or AE or 
dose-modification) then, the results must be recorded in the CRF/Clinical Trial 
Adverse Event/Special Situations Form.
Results of clinical laboratory testing will be recorded on the eCRF or be received as 
electronically produced laboratory reports submitted directly from the local or central 
laboratory.


RO7049665 — F. Hoffmann-La Roche Ltd
60/Protocol BP42698, Version 2
Additional blood or urine samples may be taken at the discretion of the Investigator if the 
results of any test fall outside the reference ranges, or clinical symptoms necessitate 
additional testing to monitor participant safety.
Where the clinical significance of abnormal laboratory results at screening is considered 
uncertain, screening laboratory tests may be repeated before randomization to confirm 
eligibility.
If there is an alternative explanation for a positive urine or blood test for drugs of abuse, 
e.g., previous occasional intake of a medication or food containing for example, codeine, 
benzodiazepines or opiates, the test could be repeated to confirm washout.
Samples collected before dosing or from participants on placebo are to be taken as a 
precautionary measure and may not be analyzed in the first instance.
8.2.5
Safety Biomarker Assessments
Quantitative changes in Treg, Teff, NK cells, and eosinophils will be evaluated as 
exploratory safety biomarkers. Cytokines, including but not limited to, IL-6, IL-8, TNF-
or IL‑1may be measured as exploratory safety biomarkers ad hoc in participants 
experiencing symptoms associated with IRRs. These assessments are described in 
Section 8.7.
Total IgE, tryptase, safety cytokines, and further exploratory safety biomarkers may be 
tested in case of participants experiencing signs and symptoms associated with IRRs
(IRR samples; see Section 1.3). This includes hypersensitivity reactions.
8.2.6
Local Pain and Skin Reactivity Assessments
Local pain and ISRs (e.g., burning, bleeding, itching, bruising, redness, hive formation, 
or other) may be assessed at any time in the study.
Participants will be asked an additional set of questions via an ISR questionnaire (see 
Appendix 6) to capture self-reported experiences of ISRs.
8.2.7
Medical History and Demographic Data
Medical history includes clinically significant diseases (including AIH and other AIDs),
surgeries, cancer history (including prior cancer therapies and procedures), reproductive 
status, smoking history, use of alcohol and drugs of abuse and all medications (e.g.,
prescription drugs, OTC drugs, herbal or homeopathic remedies, nutritional 
supplements) used by the participant within 14 days prior to the screening visit.
Demographic data will include age, sex, and self‑reported race/ethnicity.


RO7049665 — F. Hoffmann-La Roche Ltd
61/Protocol BP42698, Version 2
8.3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
The definitions of an AE or SAE can be found in Appendix 2. The NSAESI are discussed 
in Section 8.3.6.
The Investigator and any qualified designees are responsible for ensuring that all AEs 
(including assessment of seriousness, severity, and causality; see Appendix 2) are 
recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with 
instructions provided in this section and in Appendix 2.
Procedures used for recording AEs are provided in Appendix 3.
8.3.1
Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2.
Investigators will seek information on AEs at each participant’s contact. All AEs, whether 
reported by the participant or noted by study personnel, will be recorded in the 
participant’s medical record and on the Adverse Event eCRF as detailed below.
After informed consent has been obtained but prior to initiation of study treatment, 
only SAEs caused by a protocol-mandated intervention should be reported (e.g., SAEs 
related to invasive procedures such as biopsies). Any other AE should not be reported.
After initiation of study treatment, all AEs, regardless of relationship to study 
treatment, will be reported until the follow-up visit, which is scheduled 28 days after last 
dose of study treatment.
Post-study AEs and SAEs: The Investigator is not required to actively monitor 
participants for AEs after the end of the AE reporting period (e.g., follow-up visit).
However, if the Investigator learns of any SAE (including a death) or other AEs of 
concern that are believed to be related to prior treatment with study treatment, at any 
time after a participant has been discharged from the study, and the Investigator 
considers the event to be reasonably related to the study treatment or study 
participation, the Investigator must promptly notify the Sponsor. For the procedure of 
reporting, see Appendix 2.
8.3.2
Method of Detecting Adverse Events and Serious Adverse 
Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended 
and non-leading verbal questioning of the participant is the preferred method to inquire 
about AE occurrence.


RO7049665 — F. Hoffmann-La Roche Ltd
62/Protocol BP42698, Version 2
A consistent methodology of non-directive questioning should be adopted for eliciting AE
information at all participant evaluation time-points.
8.3.3
Follow-Up of Adverse Events and Serious Adverse Events
8.3.3.1
Investigator Follow-Up
The Investigator should follow up each AE until the event has resolved to baseline grade 
or better, the event is assessed as stable by the Investigator, the event is otherwise 
explained, the participant is lost to follow-up (Section 7.3), or the participant withdraws 
consent. Every effort should be made to follow all SAEs considered to be related to 
study treatment or study-related procedures until a final outcome can be reported.
During the study period, resolution of AEs (with dates) should be documented on the 
Adverse Event eCRF and in the participant’s medical record to facilitate source data 
verification. If, after follow-up, return to baseline status or stabilization cannot be 
established, an explanation should be recorded on the Adverse Event eCRF.
All pregnancies reported during the study should be followed until pregnancy outcome 
and reported according to the instructions provided in Section 8.3.5.
8.3.3.2
Sponsor Follow-Up
For SAEs, NSAESIs, and pregnancies, the Sponsor or a designee may follow up by 
telephone, fax, electronic mail, and/or a monitoring visit to obtain additional event details 
and outcome information (e.g., from hospital discharge summaries, consultant reports, 
autopsy reports) in order to perform an independent medical assessment of the reported 
event.
8.3.4
Regulatory Reporting Requirements for Serious Adverse
Events
Prompt notification by the Investigator to the Sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety 
of a study treatment under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and Investigators. 
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and Sponsor policy and forwarded 
to Investigators as necessary. 
An Investigator who receives an Investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will


RO7049665 — F. Hoffmann-La Roche Ltd
63/Protocol BP42698, Version 2
review and then, file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.
For immediate and expedited reporting requirements from Investigator to Sponsor and 
from Sponsor to Health Authority, Investigators, IRB and IEC; see Appendix 2.
8.3.4.1
Emergency Medical Contacts
To ensure the safety of study participants, access to the Medical Monitors is available 
24 hours a day, 7 days a week. Details will be available separately.
8.3.5
Pregnancy
WOCBP will be instructed to immediately inform the Investigator if they become 
pregnant during the study or within 28 days after the final dose of study treatment.
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the pregnancy reporting process as detailed 
in Appendix 5.
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs (Appendix 5).
8.3.6
Non-Serious Adverse Events of Special Interest
NSAESIs are required to be reported by the Investigator to the Sponsor immediately 
(i.e., no more than 24 hours after learning of the event; see Appendix 2 for reporting 
instructions).
NSAESIs for this study include the following:

Cases of an elevated ALT or AST in combination with either an elevated bilirubin or 
clinical jaundice, as defined in Appendix 3.

Suspected transmission of an infectious agent by the study treatment, as defined 
below:
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a participant exposed to a medicinal product. This term applies only
when a contamination of the study treatment is suspected.

NCI CTCAE (v5.0) Grade 2 IRRs and any hypersensitivity.
8.3.7
Management of Specific Adverse Events
Treatment of AEs will be considered on a case-by-case basis according to local 
standard of care.


RO7049665 — F. Hoffmann-La Roche Ltd
64/Protocol BP42698, Version 2
IRRs have been reported with the first or second infusion/injection (e.g., of biologic 
therapies) and tend to be dose-related. Such reactions typically occur during, shortly 
after or within 24 hours after study treatment administration. 
“IRR” is a basket term including other terms such as anaphylaxis, anaphylactoid 
reactions, complement activation-related pseudoallergy, and cytokine release syndrome. 
Combinations of IRR types may occur in the same patient (Doesseger et al. 2015). A 
localized ISR is not by itself considered an IRR.
IRR symptoms may be indistinguishable from an anaphylaxis type 1 hypersensitivity 
reaction (i.e., flushing, rash, respiratory difficulty, hypotension, tachycardia); however, 
hypersensitivity reactions (IgE-mediated) generally do not occur with the first exposure 
to a compound (e.g., biologic therapy).
The participant should be monitored until complete resolution of the symptoms and 
treated as clinically indicated.
An IRR blood sample will be taken in all participants at baseline (Day 1 at pre-dose) (see
Section 1.3). In case a Grade 2 IRR occurs, unscheduled PK and IRR samples will be 
collected and analyzed. The baseline samples of all participants may be analyzed as 
appropriate.
In case of signs/symptoms of IRRs in a given arm, IRR risk mitigation steps may be 
implemented in the remaining participants of the dose level. In order to reduce the 
occurrence and potential impact of IRRs, pre-medication (e.g., anti-histamine) may be 
applied after discussion between the Sponsor Clinical Pharmacologist, the Investigator, 
the safety science leader, and the Medical Monitor(s).
8.4
TREATMENT OF OVERDOSE
Study treatment overdose is the accidental administration of a drug in a quantity that is 
higher than the assigned dose. An overdose or incorrect administration of study 
treatment is not an AE unless it results in untoward medical effects (see Sections 5 and 
5.2 of Appendix 2 for further details).
Decisions regarding dose-interruptions or modifications (if applicable) will be made by 
the Investigator in consultation with the Medical Monitor based on the clinical evaluation 
of the participant.
In the event of an overdose, the Investigator should:
1.
Contact the Sponsor’s Medical Monitor immediately.
2.
Closely monitor the participant for AE/SAE and laboratory abnormalities until 
resolved.
3.
Document the quantity of the excess dose in the eCRF.


RO7049665 — F. Hoffmann-La Roche Ltd
65/Protocol BP42698, Version 2
8.5
PHARMACOKINETICS
Mandatory blood samples to evaluate serum concentrations of RO7049665 will be 
collected at on-treatment visits as specified in the SoA (see Section 1.3). The date and 
time of each sample collection will be recorded in the eCRF. Serum concentrations of 
RO7049665 will be measured by specific and validated enzyme-linked immunosorbent 
assay methods.
During the course of the study, PK sampling timepoints may be modified on the basis of 
emerging data to ensure the PK of RO7049665 can be adequately characterized. 
Additional PK samples will be taken at the time of treatment discontinuation, if the 
participant experiences an injection-related AE (such as an IRR).

Placebo-treated participants may not be analyzed in the first instance, but retained 
for subsequent analysis if appropriate.

If required, remaining PK samples, or any remaining volume of blood samples, may 
also be used for assay development/validation experiments and ADA 
characterization. 
The PK samples will be destroyed 5 years after the date of final clinical study report 
(CSR). Details on sampling procedures, sample storage, and shipment are given in the 
sample documentation.
Genetic analyses will not be performed on these samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
Drug concentration information that may unblind the study, will not be reported to 
investigative sites or blinded personnel until the study has been unblinded.
For participants who consent to RBR, leftover samples will be transferred to RBR (see 
Section 8.9).
8.6
IMMUNOGENICITY ASSESSMENTS
As RO7049665 is a fusion protein that consists of two human IL-2 muteins covalently 
linked to a human monoclonal antibody there is a risk that ADAs could develop (see 
Section 2.3).
The date and time of each sample will be recorded in the eCRF. Additional samples will 
be taken in participants with clinical signs of hypersensitivity reaction for ADA evaluation 
(see SoA Section 1.3). In each case, for each collected ADA sample, a corresponding 
PK sample will be collected at the same timepoint for the determination of the 
RO7049665 concentration. 


RO7049665 — F. Hoffmann-La Roche Ltd
66/Protocol BP42698, Version 2
Validated ADA assays will be employed to detect ADAs against RO7049665 (in serum). 
Samples which are positive for ADA will be further characterized and their neutralizing 
capability for endogenous IL-2 will be assessed using the neutralizing antibody assay.
If required, remaining ADA samples may also be used for assay development/validation 
experiments, further ADA characterization, for compound-related exploratory analyses, 
or to help develop further blood tests, after they are used for the mentioned intended 
uses. For exploratory purposes, such as epitope characterization or IgG-IgM-isotyping,
samples may be analyzed by assays which are not fully validated.
The ADA serum samples will be destroyed 5 years after the date of final CSR. For 
participants who consent to RBR, leftover samples will be transferred to RBR (see 
Section 8.9).
Samples from placebo‑treated participants may not be analyzed in the first instance but 
may be retained for subsequent analysis if appropriate.
Details on sampling procedures, sample storage, and shipment are documented in the 
sample documentation.
8.7
PHARMACODYNAMICS AND BIOMARKERS ANALYSES
A fit for purpose biomarker strategy (Section 4.2.3) will be implemented, monitoring 
several key biomarker types.
Systemic PD will be assessed in the expected target cell population (Tregs), with the aim 
of reconfirming and further characterizing the dose-dependent effects of the drug in this 
study population. For consistency, the same technology as in prior clinical studies (flow 
cytometry) will be employed. In addition to the desired selective expansion of target 
cells, changes in other cell types of interest (including but not limited to Teffs, NK cells, 
Tfhs, B cells) will be monitored, thereby corroborating the mode of action (MoA) and 
potentially informing dose selection and clinical response.
When possible (paired baseline and on-treatment liver biopsies available), liver tissue 
changes in regulatory and effector T cells will also be measured. This will enable the 
assessment of tissue PD effects, their comparison with systemic PD observations as 
well as a preliminary evaluation of intrahepatic Treg/Teff ratio as a response predictive 
biomarker. Tissue infiltrating lymphocytes will most likely be assessed by 
immunohistochemistry (IHC), given the availability of historical liver biopsies at baseline, 
as opposed to fresh samples amenable for flow cytometry. In addition, (spatial) gene 
expression analyses (targeted genes or whole transcriptome) may be performed on liver 
biopsy-derived material for enhanced insights into MoA and activated pathways.
Select exploratory serum and/or plasma disease biomarkers will be tested for their 
diagnostic (e.g., auto-antibodies, anti-nuclear antibodies [ANA], smooth muscle 


RO7049665 — F. Hoffmann-La Roche Ltd
67/Protocol BP42698, Version 2
antibodies (SMA), LKM-1, anti-LC1, anti-SLA/LP, anti-LC1, anti-LKM3) (Galaski et al. 
2020) or progression monitoring value (e.g., IgG, IgA, IgM). 
Several soluble PD markers will be monitored, including but not limited to, sCD25, 
cytokines either mechanistically linked to the study treatment MoA (IL-5, IL-6, IL-10, 
TNF-α, and potential others) as well as cytokines or chemokines hypothesized to either 
have patient stratification potential (e.g., baseline IL-2) or an ability to be used as non-
invasive response to treatment markers (e.g., CXCL10). 
Non-invasive markers of liver fibrosis and steatosis will also be measured in the 
periphery to support MoA and provide supportive evidence for their use as surrogate 
liver function assessments. These may include but are not limited to composite scores of 
liver fibrosis.
Additional PD biomarkers and methods to obtain further confidence on the mechanism 
of action of RO7049665 in participants may be tested, including but not limited to 
epigenetic signatures of T-cell subsets, e.g., T cell-specific demethylation region.
8.7.1
Genetic and Genomic Analyses
8.7.1.1
Clinical Genotyping
A mandatory whole blood sample will be taken for DNA extraction from every participant 
in all countries where this assessment is permitted (see SoA Section 1.3).
The DNA may be used for, but analysis is not limited to:

Genetic variants of the IL-2 gene or other genes encoding proteins involved in IL-2
mediated signal transduction.

Genetic variants of pathways related to AIH or other autoimmune diseases.

Genes coding for human leukocyte antigens (i.e., HLA gene family).
Data arising from all biosamples, including samples for analyses of inherited DNA, will 
be subject to the confidentiality standards described in Section 1.4, Appendix 1. For 
participants who consent to RBR, leftover samples will be transferred to RBR (see
Section 8.9).
8.8
PHARMACODYNAMICS AND BIOMARKER SAMPLES
Samples will be collected for biomarker assessments at the time points specified in the 
Schedules of Activities (Section 1.3). Biomarkers will be evaluated as described in 
Section 8.7.
The samples may also be used for research purposes to identify biomarkers useful for 
predicting and monitoring response to and safety of RO7049665, assess PD effects of 


RO7049665 — F. Hoffmann-La Roche Ltd
68/Protocol BP42698, Version 2
RO7049665, and investigate mechanism of therapy resistance. Additional markers may 
be measured in the case that a strong scientific rationale develops.
Based on continuous analysis of the data in this study and other studies, any sample 
type and/or analysis not considered to be critical for safety may be stopped at any time if 
the data from the samples collected does not produce useful information. 
Unless otherwise specified below, samples (including blood, slides, extracts, etc.) will be 
destroyed no later than 5 years after the final CSR. For participants who consent to 
RBR, leftover samples will be transferred to RBR (Section 8.9).
Any remaining blood/tissue, or appropriate, sample type after the specified analyses 
may also be used for additional (assay) validation experiments. Samples may be used 
for research to develop methods, assays, prognostics and/or companion diagnostics 
related to IL-2, T cell subsets and autoimmune diseases.
Details on processes for collection and shipment of these samples can be found in 
separate sample documentation.
8.8.1
Mandatory Samples
The following samples for PD and biomarker research are required and will be collected 
from all participants:
8.8.1.1
Blood Sampling
Blood samples will be collected for the following assessments:

To quantify relative and absolute WBC counts (T cells, B cells, NK cells, 
eosinophils) by flow cytometry as well as to complete white blood count differential. 
Tests may include (but are not limited to) markers for quantification and 
characterization of Treg and Teff cell subsets CD3, CD4, CD8, CD25, CD127 and 
FoxP3.

A mandatory whole blood sample will be taken for DNA extraction and clinical 
genotyping from every participant. If the sample is missed on Day 1, it can be 
collected at any other scheduled visit.
8.8.1.2
Tissue Sampling
A fresh or historical liver biopsy is required prior to baseline. Provided no worsening of 
disease has occurred, a historical biopsy taken no more than 12 months prior to 
randomization is acceptable. If a FFPE block is available, it is mandatory to provide it to 
the Sponsor. An optional liver biopsy sample will be taken at 6 months after treatment 
initiation. 
The purpose is to conduct the following assessments:

Characterization of infiltrating WBCs by histology (hematoxylin and eosin-staining) 
and immunohistochemistry (IHC). IHC markers tested may include but are not 
limited to CD3, CD4, CD8, and FoxP3.


RO7049665 — F. Hoffmann-La Roche Ltd
69/Protocol BP42698, Version 2

RNA extraction on biopsy samples may be performed in order to undertake optional 
whole or targeted transcriptome gene expression analysis with or without spatial 
resolution.

Methylation signature changes induced by the study treatment indicative of 
quantitative and specific changes of T-cell subsets may be assessed.
8.8.1.3
Serum and Plasma Samples
Serum and plasma samples will be collected for the following assessments:

To measure cytokines mechanistically linked with the study treatment’s mode of 
action. Soluble biomarkers considered for testing include, but are not limited to IL-5, 
IL-6, IL-10.

To measure cytokines or chemokines with stratification (baseline IL-2) or treatment
response potential (CXCL10).

To measure disease biomarkers including but not limited to auto-antibodies (e.g. 
ANA, SMA) or immunoglobulins (e.g., IgG, IgA, IgM).

To measure non-invasive markers of liver fibrosis, e.g. but not limited to: α-2-
macroglobulin, haptoglobin, apolipoprotein A1, hyaluronic acid, procollagen III 
amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 
(TIMP-1).

Additional soluble biomarkers to obtain further confidence on mechanism of action 
of RO7049665 in humans, PD or disease markers may also be tested.
8.8.1.4
Optional Samples
An optional liver biopsy may be taken (see Section 8.8.1.2).
The ICF will contain a separate section with a separate signature field that addresses 
the use of optional samples.
8.9
SAMPLES FOR RESEARCH BIOSAMPLE REPOSITORY
8.9.1
Overview of the Research Biosample Repository
The Roche RBR is a centrally administered group of facilities for the long-term storage of 
human biologic samples, including body fluids, solid tissues, and derivatives thereof 
(e.g., DNA, RNA, proteins, peptides). The collection, storage and analysis of the RBR 
samples will facilitate the rational design of new pharmaceutical agents and the 
development of diagnostic tests, which may allow for individualized drug therapy for 
patients in the future.
Collected RBR samples will be used to achieve the following objectives:

To study the association of biomarkers with efficacy or progressive disease.

To identify safety biomarkers that are associated with susceptibility to developing 
AEs or can lead to improved AE monitoring or investigation.


RO7049665 — F. Hoffmann-La Roche Ltd
70/Protocol BP42698, Version 2

To increase knowledge and understanding of disease biology and drug safety.

To study treatment response, including drug effects and the processes of drug 
absorption and disposition. 

To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays.
8.9.2
Sample Collection
The following samples will be stored in the RBR and used for research purposes, 
including, but not limited to, research on biomarkers related to RO7049665, diseases or 
drug safety:

Leftover plasma samples

Leftover serum samples

Leftover blood samples

Leftover liver tissue samples

Leftover blood samples for DNA extraction

Leftover PBMCs prepared from blood
Samples collected for DNA extraction include, but is not limited to, genomic analysis and
may be sent to one or more laboratories for analysis of germline or somatic mutations 
via whole genome sequencing (WGS), whole exome sequencing (WES), 
next-generation sequencing, or other genomic analysis methods like spatial 
transcriptomics or other methods developed in the future.
Genomics is increasingly informing researcher's understanding of disease pathobiology. 
WGS provides a comprehensive characterization of the genome and, along with clinical 
data collected in this study, may increase the opportunity for developing new therapeutic 
approaches. Data will be analyzed in the context of this study but may also be explored 
in aggregate with data from other studies. The availability of a larger dataset will assist in 
identification of important pathways, guiding the development of new targeted agents.
Participants will not be identified by name or any other personally identifying information. 
Data generated from RBR samples will be analyzed in the context of this study but may
also be explored in aggregate with data from other studies. The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug development. 
For all samples, dates of consent and sample collection should be recorded on the 
associated RBR page of the eCRF. Details on processes for collection and shipment of 
these samples can be found in separate sample documentation.


RO7049665 — F. Hoffmann-La Roche Ltd
71/Protocol BP42698, Version 2
RBR samples will be stored and used until no longer needed or until they are exhausted. 
The RBR storage period will be in accordance with the IRB/IEC‑approved Informed 
Consent Form and applicable laws (e.g., Health Authority requirements).
The repository samples will be subject to the confidentiality standards (as described 
under Confidentiality and in Appendix 1).
8.10
MEDICAL RESOURCE UTILIZATION AND HEALTH 
ECONOMICS
For Health Economics/Medical Resource Utilization and Health Economics parameters 
see Section 8.1.1.1.
8.11
TIMING OF STUDY ASSESSMENTS
8.11.1
Screening and Pre-treatment Assessments
Written informed consent for participation in the study must be obtained before 
performing any study-specific screening tests or evaluations. Informed Consent Forms 
(ICFs) for enrolled participant and for participants who are not subsequently enrolled will 
be maintained at the study site.
All screening, and all pre-treatment assessments (related to entry criteria), must be
completed and reviewed to confirm that participants meet all eligibility criteria. The 
Investigator will maintain a screening log to record details of all participants screened 
and to confirm eligibility or record reasons for screening failure.
An Eligibility Screening Form documenting the Investigator’s assessment of each 
screened participant with regard to the protocol’s inclusion and exclusion criteria is to be 
completed by the Investigator and kept at the investigational site.
Screening and pre-treatment assessments will be performed within 28 days prior to 
Day 1, unless otherwise specified. 
8.11.2
Assessments during Treatment
Under no circumstances will participants who enroll in this study and have completed 
treatment as specified, be permitted to be allocated a new randomization number and 
re-enroll in the study.
All assessments must be performed as per SoA (Section 1.3). Assessments scheduled 
on the day of study treatment administration should be performed prior to administration 
of study treatment, unless otherwise noted in the SoAs. COAs (Section 8.1.1) should be 
performed prior to the completion of other study assessments.


RO7049665 — F. Hoffmann-La Roche Ltd
72/Protocol BP42698, Version 2
8.11.3
Assessments at Study Completion/Early Termination Visit
Participants who complete the study (defined as relapse) or discontinue from the study 
early will be asked to return to the clinic 28 days ± 3 days after the final dose of study 
treatment for a follow-up visit. 
8.11.4
Follow-Up Assessments
After the follow-up visit, AEs should be followed as outlined in the SoA (Section 1.3) and 
in Sections 8.3.1 and 8.3.3.
8.11.5
Assessments at Unscheduled Visits
For activities that are required to be performed in case of an unscheduled visit, refer to 
the SoA (Section 1.3).
9.
STATISTICAL CONSIDERATIONS
9.1
STATISTICAL HYPOTHESES 
The hypothesis associated with the primary estimand (see Section 3.1) for this study is 
that the hazard ratio (HR) for the risk of relapse in the 7.5 mg RO7049665 compared 
with that of placebo is less than 1. In other words, that 7.5 mg RO7049665 increases the 
time to relapse following forced tapering of CCS/NSI therapy in participants with 
confirmed AIH who have been in stable biochemical remission for at least two years (or 
less if according to the local practice) and on stable AIH treatment for at least 3 months 
prior to randomization (and who have not had a dose increase 6 months prior to 
randomization).  
Six months after the start of CCS tapering, the relapse rate on placebo is assumed to be 
45% (van Gerven 2013). It is estimated that treatment with RO7049665 will reduce the 
relapse rate to 15%. Under the assumption of exponential times to relapse, these 
six-month relapse rates imply mean times to relapse of 10.0 months in the placebo arm
and 36.9 months in the treatment arm, leading to a reference hazard ratio of 0.272.
The hypotheses formally tested in this study are
H0: HR =1 vs H1: HR < 1
9.2
SAMPLE SIZE DETERMINATION
The sample size for this study is based on independent pairwise comparisons of each 
RO7049665 group—i.e., high dose (7.5 mg) and low dose (3.5 mg) with placebo. The
total sample size required is obtained by multiplying the appropriate per-group size by 
three. Methods for the control of the family-wise error rate are described both in this 
section and in Section 9.3.


RO7049665 — F. Hoffmann-La Roche Ltd
73/Protocol BP42698, Version 2
The reference treatment effect is 0.272. The study will use an overall one-sided type 1 
error rate (significance level) of 2.5%. A power of 90% against the reference treatment 
effect is required.
There will be one opportunity to stop for success before the end of the study, at 50% 
information. An O’Brien-Fleming-like alpha-spending rule will preserve the type 1 error 
rate. The success boundary will be binding.
There will be two opportunities to stop for futility before the end of the study: once at 
25% information (i.e., when 25% of the maximum number of events have occurred) and
once at 50% information (i.e. when 50% of the maximum number of events have 
occurred). A Pocock-like beta-spending rule will preserve power of the study. The futility 
boundary will be non-binding.
If the proportional hazards assumption holds, these assumptions imply that 29.1 events 
(i.e., 30 events for all practical purposes) in the placebo and 7.5 mg RO7049665 arms 
combined are required to achieve the desired power and significance levels.
Under the assumption that recruitment to the study will take approximately 19 months, 
that sites will be activated at uniform rate for six months, after which recruitment will 
plateau, and that follow-up should continue for at most 6 months after the last patient to 
enter the study is randomized, then recruitment of 28 participants per arm will generate 
the required number of events.
Table 9
Summary of the Group Sequential Design
Stage
Interim 1
Interim 2
End of study 
Information rate
25%
50%
100% 
Efficacy boundary (z-value scale)

2.963
1.969 
Futility boundary (z-value scale)
0.046
0.738
Number of subjects a,c
31
47
56
Cumulative number of events a
7.3
14.5
29.1
Analysis time b,c
11.7
16.3
25.0
Cumulative alpha spent
0.0001
0.0015
0.025
Cumulative power
0.0001
0.3159
0.9000
One-sided local significance level
N/A
0.0015
0.0245d
Efficacy boundary (t)
N/A
0.211
0.482
Futility boundary (t)
1.035
0.679
Overall exit probability (under H0)
0.4815
0.3136
Exit probability for efficacy (under H0)
0.0001
0.0015
Exit probability for efficacy (under H1)
0.0001
0.3159
Exit probability for futility (under H0)
0.4815
0.3121


RO7049665 — F. Hoffmann-La Roche Ltd
74/Protocol BP42698, Version 2
a: For the two arms (the placebo arm and one of the RO7049665 arms) in question.
b: Months after FPFV.
c: Estimate.
d: The hazard ratio that gives rise to a p-value of 0.0245 at the end of study analysis is 
approximately 0.594. This is the minimum detectable difference for the study and, assuming a 
mean time to relapse of 10.0 months in the placebo arm, corresponds to a mean time to 
relapse of 16.9 months on RO7049665.
Thus, the study is expected to recruit 3 × 28 = 84 participants in total and run for no 
longer than 25 months from FPFV to LPLV. If the enrolment rate or event rate differ from 
the assumptions used in these calculations, then either the number of participants or the 
duration of follow-up (or both) may be varied in order to ensure that the required number 
of events is observed.
Sample size calculations were performed using R package version 2.0.6 (Wassmer and
Pahlke, 2019). Details are filed in the study electronic Trial Master File (eTMF).
9.3
MULTIPLICITY
There are three sources of multiplicity in this study: multiplicity due to interim analyses,
multiplicity due to multiple doses, and multiplicity due to multiple endpoints.
The overall type 1 error rate for the study is protected against multiplicity due to interim 
analyses, because of the alpha- and beta-spending rules described in the preceding 
section.
The overall type 1 error rate for the study will be protected against multiplicity due to 
multiple doses by using a step-down, or gatekeeper, procedure. The statistical 
significance of the difference in response between the 3.5 mg RO7049665 group and 
the placebo group will be assessed if and only if the corresponding difference between 
the 7.5 mg RO7049665 and placebo has already been shown to be statistically 
significant.
The study has a single primary endpoint, corresponding to the single primary estimand.  
All other endpoints are secondary or exploratory. Therefore, no adjustment to nominal 
p-values will be made to protect the overall type 1 error rate for the study against 
multiplicity of endpoints.


RO7049665 — F. Hoffmann-La Roche Ltd
75/Protocol BP42698, Version 2
9.4
ANALYSES SETS
For purposes of analysis, the following analysis sets are defined in Table 10.
Table 10 Analysis Sets
Analysis set
Description
Intent-to-treat
All randomized participants will be included in the 
intent-to-treat analysis set.
Safety
All participants randomized to study treatment and who 
received at least one dose of the study treatment, whether 
prematurely withdrawn from the study or not, will be included 
in the safety analysis. 
Immunogenicity
Participants who had at least one pre-dose or at least one 
postdose ADA assessment will be included and analyzed 
according to the treatment they actually received or were 
allocated to receive. The relationship between ADA status and 
safety, efficacy, PK, and biomarker endpoints will be analyzed
and reported descriptively via subgroup analyses.
PK
Participants who had at least one pre-dose or at least one 
evaluable postdose PK sample will be included and analyzed 
according to the treatment they actually received.
Note: The analysis set for the primary estimand is defined by the estimand itself. However, 
unless there are any participants who are misdiagnosed and who subsequently enter the study 
(or other unlikely protocol violations), the intent-to-treat analysis set will be identical to the 
population for the primary estimand.
9.5
STATISTICAL ANALYSES
9.5.1
Demographics and Baseline Characteristics
Summaries for categorical baseline variables will include counts and frequencies.  
Summaries for continuous baseline variables will include counts, means, and standard 
deviations. Participants in the ITT analysis set will contribute to baseline summaries.
For each variable, the “baseline value” will be the last non-missing value obtained prior 
to the first administration of study treatment.
9.5.2
Efficacy and Pharmacodynamic Analyses
9.5.2.1
Primary Estimand
The hazard ratio will be derived from a Cox proportional hazards model for time until 
relapse with fixed effects for treatment arm, sex, and CCS use, expressed as equivalent 
prednisolone dose. The raw and median unbiased point estimates for the HR will be 


RO7049665 — F. Hoffmann-La Roche Ltd
76/Protocol BP42698, Version 2
presented together with associated confidence intervals and p-value. The estimated 
6-month relapse rates for each arm will be presented, together with associated 
confidence intervals. Kaplan-Meier curves and the associated confidence intervals will 
be graphed.
Refer to Sections 3.1.3 and 8.1 for definitions of censoring and relapse.
9.5.2.2
Secondary Endpoints
No formal hypothesis testing will be conducted for any secondary endpoint.
Changes in ALT and IgG
Values of ALT and IgG (both absolute and relative to ULN) will be plotted over time, 
grouped by treatment arm. Values (both absolute and relative to ULN) and changes from 
baseline will be tabulated.
For the safety analyses, see Section 9.5.3.
9.5.2.3
Exploratory Endpoints
Clinical Outcome Assessment
Absolute values and changes from baseline for PRO data will be tabulated by visit and 
treatment group. Where appropriate, both the overall and individual domain scores will 
be summarized (see Section 8.1.1 for further details).
Auto-antibodies
Absolute values and changes from baseline will be tabulated by visit and treatment 
group.

Titers of auto-antibodies specific for type 1, 2, or 3 AIH.

Titers for ANAs and/or anti-smooth muscle antibodies.
Cytokines
Absolute values and changes from baseline of inflammatory and anti-inflammatory 
cytokines will be tabulated by visit and treatment group.
Liver-residing Regulatory T-cells
Absolute values and changes from baseline of liver-residing Treg and Teff cells and the 
Treg/Teff ratio will be tabulated by visit and treatment group.
Liver Fibrosis
Raw Fibroscanresults (controlled attenuation parameter [CAP] scores in dB/m and 
pressure readings in kPa) will be tabulated by visit and treatment group, together with 
derived steatosis grades and fibrosis scores.
Component laboratory test results (alpha-2-macroglobulin, haptoglobin, apolipoprotein 
A1, GGT, Total bilirubin, ALT, hyaluronic acid, PIIINP and TIMP-1) will be tabulated by 


RO7049665 — F. Hoffmann-La Roche Ltd
77/Protocol BP42698, Version 2
visit and treatment group. If calculated, derived liver fibrosis test scores will be tabulated 
by visit and treatment group. If at least one required laboratory test result is not available 
at a visit, the derived test score will also be missing: there will be no imputation of 
missing laboratory test results.
Liver fibrosis scores from histology will be tabulated by visit and treatment group. Other 
liver histology findings will be presented in listings.
IgA and IgM
Absolute values and changes from baseline of total IgA and total IgM will be tabulated by 
visit and treatment group.
Pharmacodynamic Markers

Systemic Treg, Teff, Tfh, B cells, sCD25 and in tissue may be used for modeling and
simulation together with efficacy parameters.

Absolute values and changes from baseline of Treg, Teff, Tfh, and B-cell counts in 
peripheral blood and tissue will be plotted over time, grouped by treatment group, 
and tabulated by visit and treatment group.
9.5.3
Safety Analyses
All safety analyses (see Table 11) will be based on the safety analysis population 
grouped according to the treatment assigned at randomization (see Table 10).


RO7049665 — F. Hoffmann-La Roche Ltd
78/Protocol BP42698, Version 2
Table 11
Safety Statistical Analysis Methods
Endpoint
Statistical Analysis Methods
Adverse events
The original terms recorded on the eCRF by the Investigator for AEs will be 
coded by the Sponsor.
Adverse events will be summarized by mapped term and appropriate 
thesaurus level. Incidence, nature and severity of AEs, number of 
participants with SAEs, treatment-related SAEs, SAEs leading to 
discontinuation, treatment-related AEs, or AEs leading to discontinuation 
will be tabulated.
Clinical laboratory 
tests
All clinical laboratory data will be stored on the database in the units in 
which they were reported. Laboratory test values will be presented in 
International System of Units (SI units; Système International d’Unités) by 
individual outputs with flagging of abnormal results. In addition, tabular 
summaries will be used, as appropriate. Laboratory data not reported in SI 
units will be converted to SI units before processing.
Vital signs
Vital signs data and weight data will be presented with flagging of values 
outside the normal ranges and flagging of abnormalities. In addition, tabular 
summaries will be used, as appropriate.
ECG data analysis ECG data will be presented using appropriate outputs, with flagging of 
values outside the normal ranges and abnormalities. In addition, tabular 
summaries will be used, as appropriate.
Concomitant 
medications
The original terms recorded on the participants’ eCRF by the Investigator 
for concomitant medications will be standardized by the Sponsor by utilizing 
a mapped term and appropriate drug dictionary level.
Concomitant medications will be presented using appropriate outputs.
9.5.4
Pharmacokinetic Analyses
RO7049665 concentration data will be pooled with data from other studies for population 
PK and PK/PD modeling. The methods and results of that population modeling will be 
reported separately. 
9.5.5
Immunogenicity Analyses
The immunogenicity analyses will include all participants with at least one ADA 
assessment, irrespective of whether or not the participant receives any treatment
(Shankar et al., 2014).
The numbers and proportions of ADA-positive participants and ADA-negative
participants at baseline (baseline prevalence) and after study treatment administration 
(post-baseline incidence during both the treatment and follow-up periods) will be 
summarized.


RO7049665 — F. Hoffmann-La Roche Ltd
79/Protocol BP42698, Version 2
The following definition applies to post-baseline samples:

Participants are considered to be ADA positive if they are ADA negative at baseline 
but develop an ADA response following study treatment administration 
(treatment-induced ADA response), or if they are ADA positive at baseline and the 
titer of one or more post-baseline samples is greater than the titer of the baseline 
sample by a scientifically reasonable margin such as 4-fold (treatment-enhanced 
ADA response).

Participants are considered to be ADA negative if they are ADA negative at baseline 
and all post-baseline samples are negative, or if they are ADA positive at baseline 
but do not have any post-baseline samples with a titer that is greater than the titer of 
the baseline sample by a scientifically reasonable margin such as 4-fold (treatment 
unaffected).
The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
will be analyzed and reported descriptively via subgroup analyses.
9.6
INTERIM ANALYSES 
Formal interim analyses form an integral part of the analytical strategy for this study and 
are defined in Section 9.2. During the conduct of each interim analysis, the study team 
will remain blind to the results of the interim analysis. The interim analysis will be 
conducted by the statistician who is a member of the study IMC and independent from 
the study team and its results reviewed by the IMC as a whole.  
It is unlikely that the interim (or final) analyses will be conducted precisely at the 
information fractions assumed in the sample size calculation.  In this case, the stopping 
boundaries for both success and futility will be adjusted to take account of the actual 
information fractions at which the interim (and final) analyses were actually conducted 
while at the same time protecting the overall type 1 and type 2 errors of the study.
A further complication is that the planned timing of each interim analysis depends on the 
number of relapses observed in the 7.5 mg RO7049665 and placebo groups combined.  
This is a double-blind, three-arm study, so this number cannot be known without 
breaking the blind on a regular basis. Therefore, the timing of the interims will be 
estimated by looking at the number of relapses in the study as a whole, with conduct of
the interims and the final analysis when the total number of relapses is expected to be 
1.5 times greater than the number of events given in Section 9.2; that is, when 12, 23,
and 45 events have been observed in the whole study.
The IMC charter will describe the planned interim analyses in detail. 


RO7049665 — F. Hoffmann-La Roche Ltd
80/Protocol BP42698, Version 2
9.7
SUMMARIES OF CONDUCT OF STUDY
All protocol deviations will be listed. Data for study treatment administration and 
concomitant medication will be listed. The number of participants who were randomized, 
discontinued, and completed the study will be summarized and listed.


RO7049665 — F. Hoffmann-La Roche Ltd
81/Protocol BP42698, Version 2
10.
REFERENCES
Brooks R. EuroQol: the current state of play. Health Policy 1996;37:5372.
Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver 
Int 2009;29:81623.
Doessegger L, Banholzer ML. Clinical development methodology for infusion-related 
reactions with monoclonal antibodies. Clin Transl Immunology 2015;4:e39.
Dyson JK, Wong LL, Bigirumurame T, et al. Inequity of care provision and outcome 
disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 
2018;48:95160.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: 
Autoimmune hepatitis [published correction appears in J Hepatol 2015;63:1543-4]. 
J Hepatol 2015;63(4):9711004. 
EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of 
life. Health Policy 1990;16:199208.
Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory 
bowel disease: systematic review and meta-analysis. Am J Gastroenterol 
2011;106:5909.
Galaski J, Weiler-Normann C, Schakat M, et al. Update of the simplified criteria for 
autoimmune hepatitis: evaluation of the methodology for immunoserological 
testing. J Hepatol 2020;S0168-8278(20)30485-2.
Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet 
2013;382:1433-44.
Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of 
autoimmune hepatitis. Hepatology. 2008;48(1):169-176. doi:10.1002/hep.22322.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:172736.
Investigator’s Brochure RO7049665.
Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L 
compared to the EQ-5D-3L across eight patient groups: a multi-country study. 
Qual Life Res 2013;22:171727.
Lammert C, McKinnon EJ, Chalasani N, et al. Novel HLA Class I Alleles Outside the 
Extended DR3 Haplotype Are Protective against Autoimmune Hepatitis. Clin 
Transl Gastroenterol 2019;10:e00032.
Lohse AW, Sebode M, Jørgensen MH, et al. Second-line and Third-line therapy for 
Autoimmune Hepatitis A position statement from the European Reference Network 
on Hepatological Diseases and the International Autoimmune Hepatitis Group 


RO7049665 — F. Hoffmann-La Roche Ltd
82/Protocol BP42698, Version 2
[published online ahead of print, 2020 Jul 21]. J Hepatol. 2020;S0168-
8278(20)30470-0.
Lowe D, John S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World 
J Hepatol 2018;10:91123.
Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune 
Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the 
American Association for the Study of Liver Diseases. Hepatology 
2019;72:671-722.
Mackay IR, Gajdusek DC. An autoimmune reaction against human tissue antigens in 
certain acute and chronic diseases. II. Clinical correlations. AMA Arch Intern Med 
1958;101:3046.
Sebode M, Kloppenburg A, Aigner A, et al. Population-based study of autoimmune 
hepatitis and primary biliary cholangitis in Germany: rising prevalences based on 
ICD codes, yet deficits in medical treatment. Z Gastroenterol. 2020;58:4318.
Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical 
immunogenicity of therapeutic proteins and peptides-harmonized terminology and 
tactical recommendations. AAPS J 2014;16:658-73. 
Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in 
autoimmune hepatitis are associated with treatment response and depleted with 
current therapies. J Hepatol 2014;61:110614.
van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal 
of immunosuppressive medication in patients with autoimmune hepatitis in 
remission. J Hepatol 2013;58:141–7.
Waldenström JL. Blutproteine und Nahrungseiweiss. Deutsch Z Verdau Stoffwechselkr 
1950;15:113–9.
Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of 
scales and preliminary tests of reliability and validity. Med care 1996;34:220-33.
Wassmer G, Pahlke F. Confirmatory adaptive clinical trial design and analysis. 2019. R 
package version 2.0.6. Available from: https://CRAN.R-project.org/package=rpact.
Wolf DC. Autoimmune Hepatitis. MedScape 2019 Available from: 
https://emedicine.medscape.com/article/172356-overview.


RO7049665 — F. Hoffmann-La Roche Ltd
83/Protocol BP42698, Version 2
11.
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
The following section includes standard appendices such as 

Appendix 1 (Regulatory, Ethical and Study Oversight Considerations),

Appendix 2 (AE: Definitions, Reporting, Procedures for Evaluating, Follow-up, and 
Reporting) 

Appendix 3 (Procedures of Recording Adverse Events),

Appendix 4 (Clinical Laboratory Tests),

Appendix 5 (Contraceptive Guidance and Collection of Pregnancy Information).

Appendix 6 (Patient-Reported Outcome [PRO] Assessments)


RO7049665 — F. Hoffmann-La Roche Ltd
84/Protocol BP42698, Version 2
Appendix 1
Regulatory, Ethical, and Study Oversight Considerations
1.
REGULATORY AND ETHICAL CONSIDERATIONS
1.1.
COMPLIANCE WITH LAWS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual. The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting). Studies conducted in the United States or under a U.S. 
Investigational New Drug (IND) application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws. Studies conducted in the EU/EEA will comply 
with the EU Clinical Trial Directive (2001/20/EC).
1.2.
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE
This protocol, the ICFs, any information to be given to the participant (e.g. 
advertisements, diaries etc), and relevant supporting information must be submitted to 
the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC 
before the study is initiated. In addition, any participant recruitment materials must be 
approved by the IRB/EC.
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by the IRB/EC. Investigators are also 
responsible for promptly informing the IRB/EC of any protocol amendments 
(Section 2.3.1 of this Appendix).
The Investigator should follow the requirements for reporting all s to the Sponsor. 
Investigators may receive written IND safety reports or other safety‑related 
communications from the Sponsor. Investigators are responsible for ensuring that such 
reports are reviewed and processed in accordance with Health Authority requirements 
and the policies and procedures established by their IRB/EC, and archived in the site’s 
study file.
1.3.
INFORMED CONSENT
The Sponsor’s Master Informed Consent Form (and ancillary sample ICFs such as a 
Child’s Assent or Caregiver's Informed Consent Form, if applicable) will be provided to 
each site. If applicable, it will be provided in a certified translation of the local language. 
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 
50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act 
(HIPAA) requirements, where applicable, and the IRB/IEC or study center. The Sponsor 


RO7049665 — F. Hoffmann-La Roche Ltd
85/Protocol BP42698, Version 2
or its designee must review and approve any proposed deviations from the Sponsor's 
sample ICFs or any alternate consent forms proposed by the site (collectively, the 
“Consent Forms”) before IRB/EC submission. The final IRB/EC‑approved Consent 
Forms must be provided to the Sponsor for Health Authority submission purposes 
according to local requirements. Participants must be re-consented to the most current 
version of the ICF(s) during their participation in the study. A copy of the ICF(s) signed 
by all parties must be provided to the participant.
The ICFs must be signed and dated by the participant before his or her participation in 
the study. The case history or clinical records for each participant shall document the 
informed consent process and that written informed consent was obtained prior to 
participation in the study.
The ICFs should be revised whenever there are changes to study procedures or when 
new information becomes available that may affect the willingness of the participant to 
take part. The final revised IRB/EC-approved ICFs must be provided to the Sponsor for 
Health Authority submission purposes if required as per local regulations.
If the ICFs are revised (through an amendment or an addendum) while a participant is 
participating in the study, the participant may be re-consented by signing the most 
current version of the ICFs or the addendum, in accordance with applicable laws and 
IRB/EC policy. For any updated or revised ICFs, the case history or clinical records for 
each participant shall document the informed consent process and that written informed 
consent was obtained using the updated/revised ICFs for continued participation in the 
study. The study team will provide guidance for which participants need to re-consent in 
the event of an update to the ICF.
A copy of each signed ICF must be provided to the participant. All signed and dated 
ICFs must remain in each participant’s study file or in the site file and must be available 
for verification by study monitors at any time.
Participants who are re-screened are required to sign a new ICF.
Consent to Participate in the Research Biosample Repository
The ICF will contain a separate section that addresses participation in the RBR. The 
Investigator or authorized designee will explain to each participant the objectives, 
methods, and potential hazards of participation in the RBR. Participants will be told that 
they are free to refuse to participate and may withdraw their samples at any time and for 
any reason during the storage period. A separate, specific signature will be required to 
document a participant’s agreement to provide optional RBR samples. Participants who 
decline to participate will not provide a separate signature.
The Investigator should document whether or not the participant has given consent to 
participate by completing the RBR Sample Informed Consent eCRF.


RO7049665 — F. Hoffmann-La Roche Ltd
86/Protocol BP42698, Version 2
In the event of death or loss of competence of a participant who is participating in the 
research, the participant's samples and data will continue to be used as part of the RBR.
Approval by the Institutional Review Board or Ethics Committee
Collection, storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the ICF by each site's 
IRB/EC and, if applicable, an appropriate regulatory body. If a site has not been granted 
approval for RBR sampling, this section of the protocol will not be applicable at that site
Withdrawal from the Research Biosample Repository
Participants who give consent to provide samples for the RBR have the right to withdraw 
their samples at any time for any reason. If a participant wishes to withdraw consent to 
the testing of his or her samples, the Investigator must inform the Medical Monitor and 
Site Monitor in writing of the participant’s wishes using the RBR Withdrawal Form and, if 
the study is ongoing, must enter the date of withdrawal on the RBR Withdrawal of 
Informed Consent eCRF. The participant will be provided with instructions on how to 
withdraw consent after the study is closed. A participant's withdrawal from Study 
BP42698 does not, by itself, constitute withdrawal of samples from the RBR. Likewise, a 
participant’s withdrawal from the RBR does not constitute withdrawal from Study
BP42698. Data already generated before time of withdrawal of consent to RBR will still 
be used.
1.4.
CONFIDENTIALITY
Participants will be assigned a unique identifier by the Sponsor. Any participant records 
or datasets that are transferred to the Sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred. 
The participant must be informed that his/her personal study-related data will be used by 
the Sponsor in accordance with local data protection law. The level of disclosure must 
also be explained to the participant. 
Medical information may be given to a participant’s personal physician or other 
appropriate medical personnel responsible for the participant’s welfare, for treatment 
purposes.
The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.
Study data, which may include data on germline mutations, may be submitted to 
government or other health research databases or shared with researchers, government 
agencies, companies, or other groups that are not participating in this study. These data 


RO7049665 — F. Hoffmann-La Roche Ltd
87/Protocol BP42698, Version 2
may be combined with or linked to other data and used for research purposes, to 
advance science and public health, or for analysis, development, and commercialization 
of products to treat and diagnose disease. In addition, redacted clinical study reports and 
other summary reports will be provided upon request.
Confidentiality for Research Biosample Repository
Data generated from RBR samples must be available for inspection upon request by 
representatives of national and local Health Authorities, and Roche monitors, 
representatives, and collaborators, as appropriate.
Participant medical information associated with RBR samples is confidential and may 
only be disclosed to third parties as permitted by the ICF (or separate authorization for 
use and disclosure of personal health information) signed by the participant, unless 
permitted or required by law.
Data derived from RBR sample analysis on individual participants will generally not be 
provided to study Investigators unless a request for research use is granted. The 
aggregate results of any conducted research will be available in accordance with the 
effective Roche policy on study data publication.
Genetic research data and associated clinical data may be shared with researchers who 
are not participating in the study or submitted to government or other health research 
databases for broad sharing with other researchers. Participants will not be identified by 
name or any other personally identifying information. Given the complexity and 
exploratory nature of these analyses, genetic data and analyses will not be shared with 
Investigators or participants unless required by law.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of the RBR sample data will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
Monitoring and Oversight Research Biosample Repository
Samples collected for the RBR will be tracked in a manner consistent with Good Clinical 
Practice by a quality-controlled, auditable, and appropriately validated laboratory 
information management system, to ensure compliance with data confidentiality as well 
as adherence to authorized use of samples as specified in this protocol and in the ICF. 
The Sponsor’s monitors and auditors will have direct access to appropriate parts of 
records relating to participant participation in RBR for the purposes of verifying the data 
provided to the Sponsor. The site will permit monitoring, audits, IRB/EC review, and 
Health Authority inspections by providing direct access to source data and documents 
related to the samples.


RO7049665 — F. Hoffmann-La Roche Ltd
88/Protocol BP42698, Version 2
1.5.
FINANCIAL DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate Health Authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for one year after completion of the study (i.e., LPLV).
2.
DATA HANDLING AND RECORD
2.1.
DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES
2.1.1.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (e.g., laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.
2.1.2.
Clinical Outcome Assessment Data
2.1.2.1
Electronic Clinical Outcome Assessment Data 
An eCOA device will be used to capture COA data. The data will be transmitted to a 
centralized database at the eCOA vendor and the data may be reviewed by site staff via 
secure access.
eCOA data will be collected using an electronic device provided by an eCOA vendor. 
The device is designed for entry of data in a way that is attributable, secure, and 
accurate, in compliance with U.S. Food and Drug Administration (FDA) regulations for 
electronic records (21 CFR Part 11). System backups for data stored by the Sponsor 
and records retention for the study data will be consistent with the Sponsor’s standard 
procedures.


RO7049665 — F. Hoffmann-La Roche Ltd
89/Protocol BP42698, Version 2
In the exceptional situation when the scale is not available to be administered and 
recorded via a digital device, e.g. setup delays of the electronic devices, the scale can 
be administered in paper format and transcribed into the digital device retrospectively 
upon availability of the digital device. In the case that a scale is not available in either 
paper or digital format e.g., due to licensing or translation delays, the participant may still 
be enrolled into the study and the scale would not be completed.
2.1.3.
Source Data Records
Source documents (paper or electronic) are those in which participant data are recorded 
and documented for the first time. They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, COAs (paper or eCOA), 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies of transcriptions that are certified after verification as being accurate 
and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, 
participant files, and records kept at pharmacies, laboratories, and medico‑technical 
departments involved in a clinical study.
Before study initiation, data to be entered directly into the eCRFs (i.e., no prior written or 
electronic record of the data) and considered source data must be defined in the Trial 
Monitoring Plan.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described below.
To facilitate source data verification, the Investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for trial‑related 
monitoring, Sponsor audits, and IRB/EC review. The investigational site must also allow 
inspection by applicable Health Authorities.
2.1.4.
Use of Computerized Systems
When clinical observations are entered directly into an investigational site’s 
computerized medical record system (i.e., in lieu of original hardcopy records), the 
electronic record can serve as the source document if the system has been validated in 
accordance with Health Authority requirements pertaining to computerized systems used 
in clinical research. An acceptable computerized data collection system allows 
preservation of the original entry of data. If original data are modified, the system should 
maintain a viewable audit trail that shows the original data as well as the reason for the 
change, name of the person making the change, and date of the change.


RO7049665 — F. Hoffmann-La Roche Ltd
90/Protocol BP42698, Version 2
2.1.5.
Safety Biomarker Data
Adverse event reports will not be derived from safety biomarker data by the Sponsor, 
and safety biomarker data will not be included in the formal safety analyses for this 
study.  In addition, safety biomarker data will not inform decisions on participant
management.
2.2.
RETENTION OF RECORDS
Records and documents, including signed ICF, pertaining to the conduct of this study 
must be retained by the Investigator for at least 15 years after study completion or 
discontinuation of the study, or for the length of time required by relevant national or 
local Health Authorities, whichever is longer. After that period of time, the documents 
may be destroyed, subject to local regulations. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be 
transferred to another location or party without written notification to the Sponsor.
The Sponsor will retain study data for 25 years after the final study results have been
reported or for the length of time required by relevant national or local Health Authorities.
2.3.
STUDY RECORDS
The Investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully reconstructed, including but not limited to the protocol, protocol 
amendments, ICFs, and documentation of IRB/EC and governmental approval. 
Roche shall also submit an Annual Safety Report once a year to the IEC and competent 
authorities according to local regulatory requirements and timelines of each country 
participating in the study.
2.3.1.
Protocol Amendments
Any substantial protocol amendments will be prepared by the Sponsor. Substantial 
protocol amendments will be submitted to the IRB/EC and to regulatory authorities in 
accordance with local regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to participants or any non-substantial changes, as 
defined by regulatory requirements.
2.3.2.
Publication Policy
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor 
for approval prior to submission. This allows the Sponsor to protect proprietary 
information and to provide comments based on information from other studies that may 
not yet be available to the Investigator.


RO7049665 — F. Hoffmann-La Roche Ltd
91/Protocol BP42698, Version 2
The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data. In this case, a coordinating Investigator will be designated by mutual agreement.
Any formal publication of the study in which contribution of Sponsor personnel exceeded 
that of conventional monitoring will be considered as a joint publication by the 
Investigator and the appropriate Sponsor personnel.
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
2.3.3.
Dissemination of Clinical Study Data
A description of this clinical trial will be available at http://www.ClinicalTrials.gov.
2.3.4.
Management of Study Quality
The Sponsor will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring participant safety and data integrity.  
Prior to study initiation, the Sponsor will identify potential risks associated with critical 
trial processes and data and will implement plans for evaluating and controlling these 
risks.  Risk evaluation and control will include the selection of risk-based parameters 
(e.g., adverse event rate, protocol deviation rate) and the establishment of quality 
tolerance limits for these parameters prior to study initiation. Detection of deviations from 
quality tolerance limits will trigger an evaluation to determine if action is needed.  Details 
on the establishment and monitoring of quality tolerance limits will be provided in a 
Quality Tolerance Limit Management Plan.
2.3.5.
Site Inspections
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, participants’ medical records, and eCRFs. The Investigator will 
permit national and local Health Authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.
3.
ADMINISTRATIVE STRUCTURE
3.3.
INTERNAL MONITORING COMMITTEE
A dedicated group of selected Sponsor representatives, which will be independent to 
the project, will be reviewing the safety and efficacy data of the study, and the interim 
analyses. The roles, responsibilities, membership, scope of activities, time of meetings,


RO7049665 — F. Hoffmann-La Roche Ltd
92/Protocol BP42698, Version 2
and communication plan for the IMC will be documented in an appropriate charter, but 
the IMC’s responsibilities will include primary responsibility for the conduct of the 
interim analyses and recommending, after each, whether or not the study should 
continue.
4.
STUDY AND SITE CLOSURE
The Sponsor (or designee) has the right to close the study site or terminate this study at 
any time. Reasons for terminating the study may include, but are not limited to, the 
following:

The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to participants.

Participant enrollment is unsatisfactory.
The Sponsor will notify the Investigator and Health Authorities if the study is placed on 
hold, or if the Sponsor decides to discontinue the study or development program.
Study sites will be closed upon study completion. A study site is considered closed when 
all required documents and study supplies have been collected and a study-site closure 
visit has been performed.
The Investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the Sponsor or Investigator may include 
but are not limited to:

Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local Health Authorities, the Sponsor's procedures, or GCP guidelines.

Inadequate recruitment of participants by the Investigator.

Discontinuation of further study treatment development.


RO7049665 — F. Hoffmann-La Roche Ltd
93/Protocol BP42698, Version 2
Appendix 2
Adverse Events: Definitions and Procedures for Evaluating, 
Follow-up, and Reporting
1.
DEFINITION OF ADVERSE EVENTS
According to the E2A ICH guideline for Good Clinical Practice, an adverse event is any 
untoward medical occurrence in a participant or clinical investigation participant 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment.
An adverse event can therefore be:

Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product.
Events Meeting the AE Definition:

Deterioration in a laboratory value (hematology, clinical chemistry, or urinalysis) or 
other clinical test (e.g., ECG, x-ray) that is associated with symptoms or leads to a 
change in study treatment or concomitant treatment or discontinuation from study 
treatment (see Appendix 3, Section 4).

Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency and/or intensity of the condition.

New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.

Adverse events that are related to a protocol-mandated intervention, including those
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies).

"Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE unless the relapse is unexpectedly accelerated and not in 
line with the natural history of the disease. If the “Lack of efficacy” would not require 
safety reporting such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy will be reported as AE or SAE if they fulfill the definition of an AE or SAE.
Events NOT Meeting the AE Definition:

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
the Investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.


RO7049665 — F. Hoffmann-La Roche Ltd
94/Protocol BP42698, Version 2

Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is an AE.

Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
2.
DEFINITION OF SERIOUS ADVERSE EVENTS
If an event is not an AE per definition above, then it cannot be a serious adverse event 
(SAE) even if serious conditions are met (e.g., hospitalization for signs/symptoms of the 
disease under study, death due to progression of disease).
A serious adverse event is defined as any untoward medical occurrence that at any 
dose:

Results in death.

Is life-threatening.
The term "life-threatening" in the definition of "serious" refers to an event in which 
the participant was at risk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it was more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization
(see Appendix 3).
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other 
serious criteria, the event is serious. When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

Results in persistent or significant disability/incapacity
Disability means substantial disruption of the participant’s ability to conduct normal 
life functions.
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.

Is a congenital anomaly/birth defect.

Other significant events:


RO7049665 — F. Hoffmann-La Roche Ltd
95/Protocol BP42698, Version 2
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
3.
RECORDING OF ADVERSE EVENT AND/OR SERIOUS 
ADVERSE EVENT
When an AE/SAE occurs, it is the responsibility of the Investigator to review all
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.
The Investigator will then record all relevant AE/SAE information in the CRF.
It is not acceptable for the Investigator to send photocopies of the participant’s medical 
records to Medical Monitor in lieu of completion of the eCRF.
There may be instances when copies of medical records for certain cases are requested 
by the Sponsor or its delegate. In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copies of the medical records before 
submission to the Sponsor or its delegate.
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
3.1.
ASSESSMENT OF SEVERITY
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of 
an adverse event (rated as mild, moderate, or severe, or according to a predefined 
grading criteria [e.g., NCI CTCAE]); the event itself may be of relatively minor medical 
significance (such as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by the Investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event.


RO7049665 — F. Hoffmann-La Roche Ltd
96/Protocol BP42698, Version 2
The adverse event severity grading scale for the NCI CTCAE (v5.0) will be used for 
assessing adverse event severity. Table 1 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.
Table 1
Adverse Event Severity Grading Scale
Grade
Severity
1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or 
intervention not indicated
2
Moderate; minimal, local, or non-invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3
Severe or medically significant, but not immediately life-threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; or limiting self-care activities 
of daily livingb,c
4
Life-threatening consequences or urgent intervention indicatedd
5
Death related to adverse eventd
NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.
Note: Based on the NCI CTCAE (v5.0), which can be found at: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick
_Reference_8.5x11.pdf
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc.
b Examples of self-care activities of daily living include bathing, dressing and undressing, 
feeding one's self, using the toilet, and taking medications, as performed by patients who are 
not bedridden.
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 6 of this Appendix for reporting instructions), per the definition of 
serious adverse event in Section 2.
d Grade 4 and 5 events must be reported as serious adverse events (see Section 6 for 
reporting instructions), per the definition of serious adverse event in Section 2. Grade 4 
laboratory abnormalities would only be reported as SAEs if these meets one or more of the 
conditions outlined in Section 2 (Definition of Serious Adverse Events) of Appendix 2.
3.2.
ASSESSMENT OF CAUSALITY
Investigators should use their knowledge of the participant, the circumstances 
surrounding the event, and an evaluation of any potential alternative causes to 
determine whether or not an adverse event is considered to be related to the study 
treatment, indicating "yes" or "no" accordingly. The following guidance should be taken 
into consideration:

Temporal relationship of event onset to the initiation of study treatment.

Course of the event, considering especially the effects of, discontinuation of study 
treatment, or reintroduction of study treatment.

Known association of the event with the study treatment or with similar treatments.

Known association of the event with the disease under study.


RO7049665 — F. Hoffmann-La Roche Ltd
97/Protocol BP42698, Version 2

Presence of risk factors in the participant or use of concomitant medications known 
to increase the occurrence of the event.

Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event.
For participant receiving combination therapy, causality will be assessed individually for 
each protocol-mandated therapy.
4.
FOLLOW-UP OF AES AND SAES
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor or its delegate to elucidate the nature and/or causality of the AE or SAE as fully 
as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow-up 
period, the Investigator will provide the Sponsor with a copy of any post-mortem findings 
including histopathology.
New or updated information will be recorded in the originally completed eCRF.
The Investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
5.
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical trial. The Investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the Investigator learns of the event. The following is a list 
of events that the Investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study treatment:

Serious adverse events

Non-serious adverse events of special interest (NSAESI)

Pregnancies (see Section 8.3.5)
The Investigator must report new significant follow-up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information). New significant information includes the following:

New signs or symptoms or a change in the diagnosis.

Significant new diagnostic test results.


RO7049665 — F. Hoffmann-La Roche Ltd
98/Protocol BP42698, Version 2

Change in causality based on new information.

Change in the event’s outcome, including recovery.

Additional narrative information on the clinical course of the event.
Investigators must also comply with local requirements for reporting serious adverse 
events to the local Health Authority and IRB/EC.
5.1
REPORTING REQUIREMENTS OF SERIOUS ADVERSE 
EVENTS, AND NON-SERIOUS ADVERSE EVENTS OF SPECIAL 
INTEREST
Events that Occur prior to Study Treatment Initiation
After informed consent has been obtained but prior to initiation of study treatment, only 
serious adverse events caused by a protocol-mandated intervention should be reported. 
The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided 
to Investigators should be completed and submitted to the Serious Adverse Event 
Responsible immediately (i.e., no more than 24 hours after learning of the event).
Events that Occur after Study Treatment Initiation
For reports of serious adverse events and non-serious adverse events of special interest 
(Section 8.3.6) that occur after initiation of study treatment (Section 8.3.1), Investigators 
should record all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on the appropriate Adverse Event of Special Interest/ Serious 
Adverse Event eCRF form and submit the report via the electronic data capture (EDC) 
system. A report will be generated and sent to the Sponsor’s Safety Risk Management 
department.
In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form provided to Investigators should be completed 
and submitted to the Serious Adverse Event Responsible immediately (i.e., no more 
than 24 hours after learning of the event).
Once the EDC system is available, all information will need to be entered and submitted 
via the EDC system.
Reporting of Post-Study Adverse Events and Serious Adverse Events
If the Investigator becomes aware of any other serious adverse event occurring after the 
end of the AE reporting period, if the event is believed to be related to prior study 
treatment the event should be reported directly to the Sponsor or its designee, either by 
faxing or by scanning and emailing the SAE Reporting Form using the fax number or 
email address provided to Investigators.


RO7049665 — F. Hoffmann-La Roche Ltd
99/Protocol BP42698, Version 2
5.2
REPORTING REQUIREMENTS FOR CASES OF ACCIDENTAL 
OVERDOSE OR MEDICATION ERROR
Accidental overdose and medication error (hereafter collectively referred to as "special 
situations"), are defined as follows:

Accidental overdose: accidental administration of a drug in a quantity that is higher 
than the assigned dose,

Medication error:  accidental deviation in the administration of a drug,
In some cases, a medication error may be intercepted prior to administration of the 
drug.
Special situations are not in themselves adverse events, but may result in adverse 
events. Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF. If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event). For RO7049665/placebo, adverse 
events associated with special situations should be recorded as described below for 
each situation:

Accidental overdose: Enter the adverse event term. Check the "Accidental 
overdose" and "Medication error" boxes.

Medication error that does not qualify as an overdose: Enter the adverse event term.
Check the "Medication error" box.

Medication error that qualifies as an overdose: Enter the adverse event term. Check 
the "Accidental overdose" and "Medication error" boxes. 
In addition, all special situations associated with RO7049665/placebo, regardless of 
whether they result in an adverse event, should be recorded on the Adverse Event 
eCRF and should be recorded as described below:

Accidental overdose: Enter the drug name and "accidental overdose" as the event 
term. Check the "Accidental overdose" and "Medication error" boxes.

Medication error that does not qualify as an overdose: Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expired drug 
administered) as the event term. Check the "Medication error" box.

Medication error that qualifies as an overdose: Enter the drug name and "accidental 
overdose" as the event term. Check the "Accidental overdose" and "Medication 
error" boxes. Enter a description of the error in the additional case details.

Intercepted medication error: Enter the drug name and "intercepted medication 
error" as the event term. Check the "Medication error" box. Enter a description of the 
error in the additional case details.


RO7049665 — F. Hoffmann-La Roche Ltd
100/Protocol BP42698, Version 2
As an example, an accidental overdose that resulted in a headache would require the 
completion of two Adverse Event eCRF pages, one to report the accidental overdose 
and one to report the headache. The "Accidental overdose" and "Medication error" 
boxes would need to be checked on both eCRF pages.
6.
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND 
ETHICS COMMITTEES
The Sponsor will promptly evaluate all serious adverse events and NSAESI against 
cumulative product experience to identify and expeditiously communicate possible new 
safety findings to Investigators, IRBs, ECs, and applicable Health Authorities based on 
applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the document listed below:
Study Treatment
Document
RO7049665
RO7049665 Investigator’s Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the Investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed.


RO7049665 — F. Hoffmann-La Roche Ltd
101/Protocol BP42698, Version 2
Appendix 3
Procedures for Recording Adverse Events
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.
1.
DIAGNOSIS VERSUS SIGNS AND SYMPTOMS
1.1.
INJECTION REACTIONS
Adverse events that occur during or after study treatment administration and are judged 
to be related to study treatment injection should be captured as a diagnosis (e.g., 
injection-related reaction or injection-site reaction) on the Adverse Event eCRF. If
possible, avoid ambiguous terms such as “systemic reaction”. Associated signs and 
symptoms should be recorded on the dedicated Injection Reaction eCRF. If a participant 
experiences both a local and systemic reaction to the same dose of study treatment, 
each reaction should be recorded separately on the Adverse Event eCRF, with signs 
and symptoms also recorded separately on the dedicated Injection Reaction eCRF.
1.2.
OTHER ADVERSE EVENTS 
For adverse events other than injection reactions, a diagnosis (if known) should be 
recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., 
record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded on the Adverse Event eCRF. If a diagnosis is 
subsequently established, all previously reported adverse events based on signs and 
symptoms should be nullified and replaced by one adverse event report based on the 
single diagnosis, with a starting date that corresponds to the starting date of the first 
symptom of the eventual diagnosis.
2.
ADVERSE EVENTS OCCURRING SECONDARY TO OTHER 
EVENTS
In general, adverse events occurring secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events. However, medically significant adverse events 
occurring secondary to an initiating event that are separated in time should be recorded 
as independent events on the Adverse Event eCRF. For example:

If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.


RO7049665 — F. Hoffmann-La Roche Ltd
102/Protocol BP42698, Version 2

If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.

If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.

If dizziness leads to a fall and subsequent fracture, all three events should be 
reported separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
3.
PERSISTENT OR RECURRENT ADVERSE EVENTS
A persistent adverse event is one that extends continuously, without resolution, between 
participant evaluation time-points. Such events should only be recorded once on the 
Adverse Event eCRF. The initial severity of the event should be recorded, and the 
severity should be updated to reflect the most extreme severity any time the event 
worsens. If the event becomes serious, the Adverse Event eCRF should be updated to 
reflect this.
A recurrent adverse event is one that resolves between participant evaluation 
time-points and subsequently recurs. Each recurrence of an adverse event should be 
recorded separately on the Adverse Event eCRF.
4.
ABNORMAL LABORATORY VALUES
Not every laboratory abnormality qualifies as an adverse event. A laboratory test result 
should be reported as an adverse event if it meets any of the following criteria:

Accompanied by clinical symptoms.

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation).

Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy.

Clinically significant in the Investigator’s judgment.
It is the Investigator’s responsibility to review all laboratory findings. Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g.,
alkaline phosphatase and bilirubin 5 times the upper limit of normal (ULN) associated 
with cholecystitis), only the diagnosis (i.e., cholecystitis) should be recorded on the 
Adverse Event eCRF.


RO7049665 — F. Hoffmann-La Roche Ltd
103/Protocol BP42698, Version 2
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., "elevated 
potassium", as opposed to "abnormal potassium"). If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event. For example, an elevated serum potassium level of 
7.0 mEq/L should be recorded as “hyperkalemia”.
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes. The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
5.
ABNORMAL VITAL SIGN VALUES
Not every vital sign abnormality qualifies as an adverse event. A vital sign result should 
be reported as an adverse event if it meets any of the following criteria:

Accompanied by clinical symptoms.

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation).

Results in a medical intervention or a change in concomitant therapy.

Clinically significant in the Investigator’s judgment.
It is the Investigator’s responsibility to review all vital sign findings. Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g.,
high BP), only the diagnosis (i.e., hypertension) should be recorded on the Adverse 
Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes. The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
6.
ABNORMAL LIVER FUNCTION TESTS
The finding of an elevated ALT or AST (3ULN) in combination with either an elevated 
total bilirubin (2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury. 


RO7049665 — F. Hoffmann-La Roche Ltd
104/Protocol BP42698, Version 2
Therefore, Investigators must report as an adverse event the occurrence of either of the 
following:

Treatment-emergent ALT or AST3ULN in combination with total 
bilirubin2ULN.

Treatment-emergent ALT or AST3ULN in combination with clinical jaundice.
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Appendix 2) and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event), either as a serious adverse event or a non-serious adverse event of special 
interest (see Section 8.3.6).
7.
DEATHS
All deaths that occur during the protocol-specified adverse event reporting period (see 
Section 5 of Appendix 2), regardless of relationship to study treatment, must be recorded 
on the Adverse Event eCRF and immediately reported to the Sponsor. This includes 
death attributed to progression of autoimmune hepatitis.
Death should be considered an outcome and not a distinct event. The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF. Generally, only one such event should be 
reported. If the cause of death is unknown and cannot be ascertained at the time of 
reporting, “unexplained death” should be recorded on the Adverse Event eCRF. If the 
cause of death later becomes available (e.g., after autopsy), “unexplained death” should 
be replaced by the established cause of death. The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
8.
PREEXISTING MEDICAL CONDITIONS
A preexisting medical condition is one that is present at the screening visit for this study. 
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study. When 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors (e.g.,
“more frequent headaches”).
9.
LACK OF EFFICACY OR WORSENING OF AUTOIMMUNE 
HEPATITIS
Medical occurrences or symptoms of deterioration that are anticipated as part of AIH
should be recorded as an adverse event if judged by the Investigator to have 


RO7049665 — F. Hoffmann-La Roche Ltd
105/Protocol BP42698, Version 2
unexpectedly worsened in severity or frequency or changed in nature at any time during 
the study. When recording an unanticipated worsening of AIH on the Adverse Event 
eCRF, it is important to convey the concept that the condition has changed by including 
applicable descriptors (e.g., “accelerated Auto Immune Hepatitis”).
10.
HOSPITALIZATION OR PROLONGED HOSPITALIZATION
Any adverse event that results in hospitalization or prolonged hospitalization should be 
documented and reported as a serious adverse event (per the definition of serious 
adverse event in Appendix 2), except as outlined below.
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:

Hospitalization for respite care.

Planned hospitalization required by the protocol (e.g., an optional liver biopsy).

Hospitalization for a preexisting condition, provided that all of the following criteria 
are met:
The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease.
The participant has not suffered an adverse event.
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead:

Hospitalization for an adverse event that would ordinarily have been treated in an 
outpatient setting had an outpatient clinic been available.
11.
PATIENT-REPORTED OUTCOME DATA (COA DATA 
REPORTED DIRECTLY BY PATIENTS)
Adverse event reports will not be derived from PRO data by the Sponsor, and safety 
analyses will not be performed using PRO data. Sites are not expected to review the 
PRO data. Roche study team will determine whether any PRO data elements may be 
indicative of a medically significant adverse event (e.g., suicidal ideation, worsening of 
depression, worsening of hemoptysis) and could necessitate real time review by the site 
or Sponsor.


RO7049665 — F. Hoffmann-La Roche Ltd
106/Protocol BP42698, Version 2
Appendix 4
Clinical Laboratory Tests
The tests detailed in Table 1 will be performed by the central laboratory with the 
exception of urinalysis, pregnancy testing, urine drug screen, and alcohol test. If the 
local laboratory results are used, the results must be captured in source documentation 
and entered into the eCRF.
Local laboratory results are only required in the event that the central laboratory results 
are not available in time for either study treatment administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central 
analysis is obtained at the same time. Additionally, if the local laboratory results are used 
to make either a study treatment decision or response evaluation, the results must be 
captured in source documentation and entered as a comment into the eCRF.
Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Sections 5.1 and 5.2, respectively, of the protocol.
Additional tests may be performed at any time during the study as determined necessary 
by the Investigator or required by local regulations.
Table 1
Protocol-Required Safety Laboratory Assessments


RO7049665 — F. Hoffmann-La Roche Ltd
107/Protocol BP42698, Version 2
Laboratory Assessments
Parameters
Hematology

Leucocytes, erythrocytes, hemoglobin, hematocrit, 
platelets, differential count (neutrophils, 
eosinophils, basophils, monocytes, lymphocytes).
Blood Chemistry

Sodium, potassium, chloride, CRP, bicarbonate, 
non-fasting glucose, urea, creatinine, creatine 
kinase (CK), protein, albumin, phosphate, calcium, 
total and direct bilirubin, alkaline phosphatase, 
ALT, AST, urate, GGT, IgG, IgA, IgM (IgA and IgM 
at screening, week 25, every 24 weeks thereafter
and at early termination/end of study). Cholesterol, 
LDL cholesterol, HDL cholesterol, triglycerides.
Coagulation

Prothrombin time (i.e., INR) and activated 
thromboplastin time (aPTT).
Viral Testing

Serology: HIV (specific tests HIV-1 antibody, HIV-
1/2 antibody, HIV-2 antibody), hepatitis B surface 
antigen (HBsAg), total hepatitis B core antibody 
(HBcAb) 

PCR: HCV, EBV and CMV
Hormones

Free T4, TSH

Follicle-stimulating hormone (FSH) in females
IRR sample

IgE, tryptase (and includes exploratory safety 
biomarkers, see Section 8.2.5).
Pregnancy Test

All women of childbearing potential (including 
those who have had a tubal occlusion/ligation) will 
have a blood pregnancy test at screening. Urine 
pregnancy tests will be performed at specified 
subsequent visits. If a urine pregnancy test is 
positive, it must be confirmed by a blood 
pregnancy test.
Anti-Drug Antibodies 

As specified 
Urinalysis

Specific gravity

Dipstick: pH, glucose, protein, blood. 

If there is a clinically significant positive result 
(confirmed by a positive repeated sample), urine 
will be sent to the local laboratory for microscopy 
and culture. If there is an explanation for the 
positive dipstick results (e.g., menses), it should 
be recorded and there is no need to perform 
microscopy and culture.

Microscopic examination (red blood cells [RBCs], 
white blood cells [WBCs], casts, crystals, 
epithelial cells, bacteria), if blood or protein is 
abnormal.
Other Screening Tests

Urine drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opiates, 
codeine, and benzodiazepines).

Alcohol breath test.


RO7049665 — F. Hoffmann-La Roche Ltd
108/Protocol BP42698, Version 2
The results of each local test must be entered into the CRF.
Investigators must document their review of each laboratory safety report.
Laboratory/analyte results that could unblind the study, will not be reported to 
investigative sites or other blinded personnel until the study has been unblinded.
Additional Statistical Considerations for Clinical Laboratory Data

Standard Reference Ranges and Transformation of Data
Potential analysis considerations for analyzing laboratory data includes the use of 
standard reference ranges and potential transformation of data for specific laboratory
tests. 
In this scenario, Roche standard reference ranges, rather than the reference ranges of 
the Investigator, can be used for specific parameters. For these parameters, the 
measured laboratory test result will be assessed directly using the Roche standard 
reference range. Certain laboratory parameters will be transformed to Roche’s standard 
reference ranges.
A transformation will be performed on certain laboratory tests that lack sufficiently 
common procedures and have a wide range of Investigator ranges, e.g., enzyme tests 
that include AST, ALT, and alkaline phosphatase, and total bilirubin. Since the standard 
reference ranges for these parameters have a lower limit of zero, only the upper limits of 
the ranges will be used in transforming the data.

Definition of Laboratory Abnormalities
For all laboratory parameters included in the analysis described above, there exists a 
Roche predefined standard reference range. Laboratory values falling outside this 
standard reference range will be labeled “H” for high or “L” for low in participant listings 
of laboratory data.
In addition to the standard reference range, a marked reference range has been 
predefined by Roche for these laboratory parameters. The marked reference range is 
broader than the standard reference range. Values falling outside the marked reference 
range that also represent a defined change from baseline will be considered marked 
laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not 
available for a participant, the midpoint of the standard reference range will be used as 
the participant’s baseline value for the purposes of determining marked laboratory 
abnormalities. Marked laboratory abnormalities will be labeled in the participant listings 
as “HH” for very high or “LL” for very low.


RO7049665 — F. Hoffmann-La Roche Ltd
109/Protocol BP42698, Version 2
Appendix 5
Contraceptive Guidance and Collection of Pregnancy 
Information
1.
DEFINITIONS

Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile. The definition of childbearing potential may be adapted for 
alignment with local guidelines or requirements.

Women in the following categories are considered to be Woman of Non-
Childbearing Potential (WONCBP)
a)
Pre-menarchal
b)
Pre-menopausal female with one of the following:
–
Documented hysterectomy.
–
Documented bilateral salpingectomy.
–
Documented bilateral oophorectomy.
Note: Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history interview.
c)
Post-menopausal female
–
A post-menopausal state is defined as no menses for 12 months without an 
alternative medical cause other than menopause. A high follicle-stimulating 
hormone (FSH) level in the post-menopausal range may be used to confirm a 
post-menopausal state in women not using hormonal contraception or hormonal 
replacement therapy (HRT). However, in the absence of 12 months of 
amenorrhea, a single FSH measurement is insufficient.
–
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non-hormonal highly effective contraception methods if they wish 
to continue their HRT during the study. 
–
Only discontinue HRT to allow confirmation of post-menopausal status before 
study enrollment.


RO7049665 — F. Hoffmann-La Roche Ltd
110/Protocol BP42698, Version 2
2.
CONTRACEPTION GUIDANCE

Female Participants
Female participants of childbearing potential are eligible to participate if they agree to 
use acceptable methods of contraception consistently and correctly as described in 
Table 1 below (as per CTFG guidance Section 2.3.4).
Per ICH M3(R2), highly effective methods of birth control are defined as those, alone or 
in combination, that result in a low failure rate (i.e. less than 1% per year) when used 
consistently and correctly as described in Table 1 below.
Table 1
Highly Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User-Dependenta
(Failure rate of 1% per year when used consistently and correctly)

Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation:
o
Oral
o
Intravaginal
o
Transdermal

Progestogen-only hormonal contraception associated with inhibition of ovulation:
o
Oral
o
Injectable
Highly Effective Methods That Are User-Independent
(Failure rate of 1% per year)

Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationa

Intrauterine device (IUD)

Intrauterine hormone-releasing system (IUS)

Bilateral tubal occlusion/ ligation
Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
Acceptable Birth Control Methods Which May Not Be Considered As Highly Effective
(Failure rate of 1% per year when used consistently and correctly)


RO7049665 — F. Hoffmann-La Roche Ltd
111/Protocol BP42698, Version 2

Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the
primary mode of action

Male or female condom with or without spermicide b

Cap, diaphragm or sponge with spermicide b
a)
Hormonal contraception may be susceptible to interaction with the IMP, which may reduce 
the efficacy of the contraception method.
Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
participants participating in clinical studies.
b)
A combination of male condom with either cap, diaphragm or sponge with spermicide 
(double barrier methods) are also considered acceptable, but not highly effective, birth 
control methods. i.e., when the risk of teratogenicity and genotoxicity is unlikely.
3.
PREGNANCY TESTING
For WOCBP enrolled in the study, pregnancy tests will be performed according to 
Schedule of Activity tables (see Section 1.3). If a urine pregnancy test is positive, it must 
be confirmed by a blood pregnancy test.
Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected and according to local practice.
4.
COLLECTION OF PREGNANCY INFORMATION

Female participants who become pregnant
The Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study (see Section 8.3.5 Pregnancy). 
Information will be recorded on the appropriate form and submitted to the Sponsor within 
24 hours of learning of a participant's pregnancy. The participant will be followed to 
determine the outcome of the pregnancy. The Investigator will collect follow-up 
information on the participant and the neonate, which will be forwarded to the Sponsor. 
Monitoring of the participant should continue until conclusion of the pregnancy. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy itself is not considered to be an AE or SAE, and should not be 
recorded on the AE eCRF, any pregnancy complication will be reported as an AE or 
SAE. A spontaneous abortion is always considered to be an SAE and will be reported as 
such. Any post-study pregnancy related SAE considered reasonably related to the study 
treatment by the Investigator, will be reported to the Sponsor as described in 
Appendix 2. While the Investigator is not obligated to actively seek this information in 
former study participants, he/she may learn of an SAE through spontaneous reporting.


RO7049665 — F. Hoffmann-La Roche Ltd
112/Protocol BP42698, Version 2
Any female participant who becomes pregnant while participating in the study will 
discontinue study treatment.
5
ABORTIONS
Any spontaneous abortion should be classified as a serious adverse event (as the 
Sponsor considers spontaneous abortions to be medically significant events), recorded 
on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning of the event; see Section 5 of Appendix 2).
Any induced abortion due to maternal toxicity and/or embryofetal toxicity should also be 
classified as serious adverse event, recorded on the Adverse Event eCRF, and reported 
to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5 of Appendix 2).
Elective or therapeutic abortion not associated with an underlying maternal or 
embryofetal toxicity (e.g., induced abortion for personal reasons) does not require 
expedited reporting but should be reported as outcome of pregnancy on the Clinical Trial 
Pregnancy Reporting Form.
6
CONGENITAL ANOMALIES/BIRTH DEFECTS
Any congenital anomaly/birth defect in a child born to a female participant should be 
classified as a serious adverse event, recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event).


RO7049665 — F. Hoffmann-La Roche Ltd
113/Protocol BP42698, Version 2
Appendix 6
Patient-Reported Outcome (PRO) Assessments
For PROMIS-SF Fatigue 13a it is better to use the T-score from the scoring manual or it 
may come directly from the ePRO instead of the raw score. See link to scoring manual: 
https://www.healthmeasures.net/search-view-measures
EQ-5D-5L comes with 5 questions and a VAS scale. The 5 questions needs to be 
converted to utility estimates in order to be meaningful and represent the preference of 
the general population. https://euroqol.org/wp-content/uploads/2019/09/EQ-5D-5L-
English-User-Guide_version-3.0-Sept-2019-secured.pdf
SF-12 scores can also be estimated to a normative score (see below).
The Injection-Site Reaction questionnaire (see below) is a set of questions to capture 
self-reported experience of ISRs. The questions cover four symptoms (pain, swelling, 
redness and itchiness) at a site of study treatment injection. Participants are asked if 
they experienced any of these symptoms in the past 14 days, with the response options 
being "Yes", "No" and “Not applicable”. For each symptom reported, participants are 
asked how bothersome they found the symptom based upon a 5-point Likert scale 
ranging from “Not at all” to “Very much”.


RO7049665 — F. Hoffmann-La Roche Ltd
114/Protocol BP42698, Version 2


RO7049665 — F. Hoffmann-La Roche Ltd
115/Protocol BP42698, Version 2
Injection-Site Reaction Questionnaire (shortened version)
In the last 14 days, did you have any
Yes
No
Not applicable
PAIN at a site of drug injection?
☐☐
☐
SWELLING at a site of drug injection? ☐☐
☐
REDNESS at a site of drug injection?
☐☐
☐
ITCHINESS at a site of drug injection? ☐☐
☐
Questions in the table below are conditional upon the response from the participant to 
the question in the table above.
How much did the
Not at 
all
A little 
bit
Some-
what
Quite a 
bit
Very 
much
PAIN at a site of drug injection 
bother you?
☐
☐
☐
☐
☐
SWELLING at a site of drug 
injection bother you?
☐
☐
☐
☐
☐
REDNESS at a site of drug 
injection bother you?
☐
☐
☐
☐
☐
ITCHINESS at a site of drug 
injection bother you?
☐
☐
☐
☐
☐